

INDEX

- Accessory food factors, in nutrition, 23
- Aconitase, in *Lentinus edodes*, 48
- AC-PS polysaccharide, immunomodulatory effects of, 168
- Acquired immunodeficiency syndrome (AIDS), mushrooms and, 21–22
- Active ingredients, WHO guidelines and, 202
- Adenocarcinoma, antimetastatic effects on, 171
- Adenosine diphosphate (ADP), in *Lentinus edodes*, 45
- Adenosine triphosphate (ATP), in *Lentinus edodes* genetics, 53
- AER bill, 208
- Aerobic pathways, in *Lentinus edodes*, 48
- Africa, mushroom production in, 73
- Agaricaceae, classification of, 80
- Agaricales, 35
 - classification of, 80
- Agaricus*
 - cultivation of, 14
 - in developing countries, 22
 - US regulation of dietary supplements from, 204
- Agaricus bisporus*
 - antioxidants in, 92
 - antitumor polysaccharides from, 156
 - ash and mineral content of, 76
 - classification of, 80
 - cultivation of, 14, 18
 - dietary fiber in, 77
 - edibility of, 4
 - energy content of, 78
 - hypcholesterolemic effects of, 97
 - hypolipidemic effects of, 95
 - moisture content of, 73
 - in mushroom industry, 26
 - mushroom-related hypoglycemia and, 98–99
 - protein quality of, 88
 - US regulation of HMBD from, 204
 - vitamin content of, 76–77
 - world production of, 73
- Agaricus bitorquis*, cultivation of, 14
- Agaricus blazei*, 18, 85. *See also* *Agaricus brasiliensis*
 - antimetastatic effects of, 172
 - antitumor polysaccharide–protein complexes from, 158, 160, 164
 - antitumor polysaccharides from, 154, 155, 156
 - chemical composition of, 82
 - classification of, 80
 - FWE water extract from, 158, 172
 - polysaccharide–protein complex from, 167
 - polysaccharides isolated from, 148, 150–151
 - world production of, 72, 73
- Agaricus blazei* Murill (ABM),
 - immunomodulatory effects of, 164. *See also* *Agaricus murrill*
- Agaricus brasiliensis*. *See also* *Agaricus blazei*
 - antitumor polysaccharides from, 154
 - bed preparation for, 18–19
 - biology and genetics of, 18
 - cultivation of, 18–19
 - polysaccharides isolated from, 151
- Agaricus campestris*
 - anatomy of, 3
 - mushroom-related hypoglycemia and, 98–99
- Agaricus macrosporus*, protein quality of, 88
- Agaricus murrill*, antiangiogenesis and, 173. *See also* *Agaricus blazei* Murill (ABM)
- Agaridine, US regulation of, 204
- Agriculture
 - applied mushroom biology and, 9
 - biomass waste from, 10–11
 - mushroom cultivation as, 11–12
- Agrocybe aegerita*, 58, 84
 - chemical composition of, 82
 - classification of, 80
 - hypcholesterolemic effects of, 97
 - world production of, 72, 73

- Agrocybe chaxinggu*, 85
 chemical composition of, 82
 classification of, 80
- Agrocybe cylindracea*
 antioxidants in, 90
 antitumor polysaccharides from, 154
 chemical improvement of antitumor polysaccharides from, 176
 mushroom-related hypoglycemia and, 98
 protein and amino acid content of, 74–75
- Air filters, in *Wolfiporia cocos* cultivation, 121
- Akavia, Eden, xxi, 199
- Alanine, in conventional edible mushrooms, 74, 75
- Alkaloids, in mushrooms, 88
- α -glucans
 in chemical improvement of antitumor activity, 176–177
 from mushrooms, 157
- α -tocopherol, in mushroom antioxidant assays, 90, 92
- Alternative herbal substances, European Union regulation of, 209
- Amanita*, toxicity of, 6
- Amanita muscaria*
 anatomy of, 3
 antitumor polysaccharides from, 154
 chemical improvement of antitumor polysaccharides from, 176
- Amanita phalloides*, as poisonous, 4
- Amatoxin, 6
- American Diabetic Association (ADA), on sclerotal dietary fiber, 124
- American Herbal Products Association (AHPA), 205
- Amimethylation, in chemical improvement of antitumor activity, 176
- Amino acids
 in conventional edible mushrooms, 74–75
 in cultivated mushroom dietary fiber, 77
 in dietary supplements, 200
 during early sclerotial ontogeny, 115
 in mushrooms, 88–89
- Amplified fragment length polymorphisms (AFLPs), in generating *Lentinus edodes* molecular markers, 48, 49, 50
- Anaerobic pathways, in *Lentinus edodes*, 48
- Anaerobic saccharolytic microflora, colonic fermentation and, 129, 130
- Androgen receptor (AR), 157
- Angiogenesis, 172
- Antiangiogenesis, 179
 as antitumor mechanism, 172–173
- Antiatherosclerotic effects, of mushrooms, 96
- Anticancer preparations, regulation of mushroom, 199–200
- Anticonvulsant medications, folic acid and, 217
- Antidiabetic drugs, mushroom-related hypoglycemia and, 99
- Antigenotoxicity, 179
- Antigen-presenting cells (APCs), dendritic cells as, 168
- Antimetastasis, 179
 as antitumor mechanism, 171–172
- Antioxidants, in mushrooms, 89–94
- Antiproliferation of cancer cells, as antitumor mechanism, 153–161
- Antisclerotic effects, of mushrooms, 94
- Antitumor effects
 of mushroom polysaccharides, 147–198
 of sclerotia, 132–134
 of *Wolfiporia cocos*, 120
- Antitumor polysaccharide–protein complexes, from mushrooms, 158–159
- Antitumor polysaccharides, from mushrooms, 154–157
- Antrodia camphorata*, polysaccharide from, 168
- Antrodia cinnamomea*, antiangiogenesis and, 173
- Antrodia malicola*, antiangiogenesis and, 173
- Antrodia xantha*, antiangiogenesis and, 173
- Antrodiaella liebmannii*, antiangiogenesis and, 173
- Aphylophorales, 119
 classification of, 80
- Apoptosis, 157, 159, 160, 168, 179
 antimetastatic effects on, 171
 as antitumor mechanism, 153–161
 polysaccharides and, 148, 150, 152
- Applied mushroom biology, 6, 7–11, 28–29
 impact of, 9–11
- Arabinogalactan, from mushrooms, 156
- Arabinoglucan, from mushrooms, 155
- Arabitol, in cultivated mushrooms, 78
- Arbitrary primer polymeric chain reactions (AP-PCRs), in generating *Lentinus edodes* molecular markers, 48, 49, 50, 51, 61
- Arginine, in conventional edible mushrooms, 74
- Armillariella mellea*, hypolipidemic effects of, 95
- Armillariella tubescens*
 antitumor polysaccharide–protein complexes from, 158
 antitumor polysaccharides from, 154
- Aromatic compounds
 biosynthesis of, 93
 in conventional edible mushrooms, 75
- Artificial cultivation, of *Ganoderma lucidum*, 19

- Ascomycetes, 3, 149
- Ascomycota, classification of, 80
- Ascomycotina, sclerotia of, 112
- Ash. *See also* Minerals
- in conventional edible mushrooms, 75–76
 - in nonconventional edible mushrooms, 79, 81
 - in sclerotia, 123–124
- Asia
- Lentinus edodes* from, 35
 - medicinal mushroom uses in, 25
 - medicinal uses of mushroom polysaccharides in, 147, 150
 - mushroom production in, 22, 23, 73
- Asiaticusins A/B, as mushroom antioxidants, 91, 92
- Aspartic acid, in conventional edible mushrooms, 74
- Aspergillus candidus*, biosynthesis of phenolic compounds by, 93–94
- Aspergillus oryzae*, 56, 57
- Aspergillus terreus*, hypolipidemic effects of, 95
- Atherosclerosis, hypercholesterolemia and, 94
- Atkins, F. C., 26
- ATOM polysaccharide–protein complex, 160, 167
- Auricularia*, world production of, 72, 73
- Auricularia auricula*
- antitumor polysaccharides from, 154
 - dietary fiber in, 77
 - hypolipidemic effects of, 95
- Auricularia auricula-judae*
- branching configurations of polysaccharides from, 175
 - hypocholesterolemic effects of, 97
 - mushroom-related hypoglycemia and, 98
- Auricularia fuscusuccinea*, world production of, 73
- Auricularia polytricha*, hypolipidemic effects of, 95
- Australia, 220
- introducing medicinal-mushroom dietary supplements in, 211–212
- Australia New Zealand Food Authority (ANZFA), 201, 211–212
- Australia New Zealand Food Standards Council, 211–212
- Australian Parliament, 211
- Authorized health claims, 206
- Autotrophic agents, sclerotial ontogeny and, 113
- Bacillus subtilis*, 56, 57
- Bakery products, sclerotial dietary fiber for, 128
- Barley dietary fiber, sclerotial dietary fiber versus, 126–127
- Barrier, rind as, 116
- Basic fibroblast growth factor (bFGF), antiangiogenesis and, 172
- Basidiomycetes, 3, 149
- biosynthesis of phenolic compounds by, 93
 - cell walls of, 121–122
 - dietary fiber in, 77
 - life cycles of, 37
 - proximate composition of, 124
- Basidiomycota, 35
- classification of, 80
- Basidiomycotina, 119
- sclerotia of, 112, 118
- Basidiospore formation, in *Lentinus edodes*, 44–47
- Basidiospores, of *Lentinus edodes*, 14, 37, 38
- B cells, dendritic cells and, 168
- Beds, in *Agaricus brasiliensis* cultivation, 18–19
- Befungin, regulation of, 200
- Benzoic acid, biosynthesis of, 93
- β -carotene bleaching, in mushroom antioxidant assays, 90
- β -glucans, 179
- antitumor and immunomodulatory effects of sclerotial, 132–134
 - branching configurations of, 174–175
 - in chemical improvement of antitumor activity, 176–177
 - colonic fermentation and, 130
 - conformations of, 175–176
 - in cultivated mushroom dietary fiber, 78
 - D-fraction, 167–168
 - effects on hematopoietic stem cells, 170–171
 - grifolan and, 165–166
 - in immune response, 162
 - in vivo Ca/Mg absorption and, 132
 - mushroom-related hypoglycemia and, 98
 - from mushrooms, 150, 151, 152, 153, 154–155, 157
 - schizophyllan and, 165
 - in sclerotial dietary fiber, 125
- β -glucopyranosides, from mushrooms, 150
- β -glucosidases, in mushrooms, 10
- β oxidation, in biosynthesis of phenolic compounds, 93
- Biochemistry, of sclerotia, 121–123
- Biochemopreventives, regulation of, 200
- Bioconversion efficiency, of mushrooms, 22
- Bioconversion processes, mushrooms in, 11
- Bioconversion technology, mushrooms in, 9
- Biological efficiency, of mushrooms, 22
- Biological response modifiers (BRMs)
- mushroom products as, 201
 - polysaccharides and, 148, 161–162, 178

- Biology
 of mushrooms, 6–11, 28–29
 specialization in, 7
- Biomacromolecules, polysaccharides as, 148
- Biomass by-products, reuse of, 28
- Biomass wastes, applied mushroom biology and,
 9, 10–11, 28
- Biopharmacology
 mushroom polysaccharides in, 147–148
 of sclerotia, 128–134
- Bioprocessing, mushrooms and, 8, 23, 28
- Bioremediation, mushroom, 7, 8, 9, 11, 28
- Biosynthesis
 by mushrooms, 10–11, 28
 of phenolic compounds from fungi, 93–94
- Biotechnology, mushroom, 7–8, 9, 23–25
- Bitter components, in conventional edible
 mushrooms, 75
- Black truffle, 72
- BLASTX, in *Lentinus edodes* genetics, 54
- Blood vessels, in angiogenesis, 172
- Bolbitaceae
 antioxidants in, 90
 classification of, 80
- Boletes, 72
- Boletinus asiaticus*, antioxidants in, 92
- Boletus*, 72
 ash and mineral content of, 76
 energy content of, 78
- Bone marrow cells (BMCs), 170
- Botanical products/botanicals
 in dietary supplements, 200
 regulation of, 218
 safety of, 215
- Botryotinia*, sclerotia of, 112
- Botrytis*, lipid bodies in, 123
- Botrytis cinerea*, lipid bodies in, 123
- Botrytis fabae*, lipid bodies in, 123
- Bottles, in *Ganoderma lucidum* cultivation,
 20
- Bowel function, in colonic fiber fermentation,
 129
- Bran, sclerotial dietary fiber versus, 127
- Branching configuration, of antitumor
 polysaccharides, 174–175
- Brazil, *Agaricus brasiliensis* cultivation in, 18
- Breast cancer/carcinoma
 chemical improvement of antitumor activity
 versus, 176
 GLP effects on, 163
 mushroom polysaccharides versus, 151, 159
- Brown rot fungus, *Wolfiporia cocos* as, 120–121
- Burkitt lymphoma, mushroom polysaccharide–
 protein complexes versus, 160
- CAAT box, in *Lentinus edodes* transcriptional
 regulation, 55–56
- Cadmium, in cultivated mushrooms, 76
- Caffeic acid
 biosynthesis of, 93
 as mushroom antioxidant, 92
- Calcium
 in cultivated mushrooms, 76
 in vitro sclerotial binding of, 128–129
 in mushrooms, 24
 in nonconventional edible mushrooms, 79
 in sclerotial dietary fiber, 125
- Calcium absorption, by sclerotia, 131–132
- Calories, in mushrooms, 23–24
- Canada, 220
 food safety systems in, 219–220
 introducing medicinal-mushroom dietary
 supplements in, 210–211
 mushroom nutraceutical regulation in, 201
- Cancer cell antiproliferation, as antitumor
 mechanism, 153–161
- Cancer therapy, mushrooms and, 25
- Cantharellus cibarius*, 72
 ecological classification of, 5
- Cap, in mushroom identification, 5
- Carbohydrate biosynthesis, in *Lentinus edodes*,
 45
- Carbohydrates
 in conventional edible mushrooms, 78
 in mushrooms, 24
 in nutrition, 23
 in sclerotia, 123
 during sclerotial development, 114, 115
 sclerotial extracellular matrix and, 122
- Carbon dioxide, in *Agaricus* cultivation, 14
- Carboxymethylated β -glucan (CMPTR), from
 mushrooms, 152–153, 159
- Carboxymethylation (CM), in chemical
 improvement of antitumor activity, 176
- Carcinogenesis, effects of lentinan on, 165
- Carcinoma, polysaccharide–protein complexes
 versus, 160, 167
- Cardiotonic agent, *Wolfiporia cocos* as, 120
- Cardiovascular disease
 edible mushrooms and, 71
 hypercholesterolemia and, 94
- Carmustine (BCNU), mushroom
 polysaccharides and, 150, 157
- β -Carotene bleaching, in mushroom antioxidant
 assays, 90
- Casein, protein quality of, 88
- Cbx^R marker, in *Lentinus edodes* transformation,
 58

- cDNA clones, in *Lentinus edodes* genetics, 54
 See also Complementary DNA (cDNA)
- cDNA microarray, in *Lentinus edodes* genetics, 36, 51, 53–54
- cDNA representational difference analysis (cDNA-RDA), of *Lentinus edodes*, 51, 52, 61. See also Representational difference analysis (cDNA-RDA)
- cDNA sequencing, in *Lentinus edodes*
 sequencing by synthesis, 55
- Cel* genes, in *Lentinus edodes*, 60
- Cell cycle control genes, of *Lentinus edodes*, 40
- endo*-Cellobiohydrolase, *Lentinus edodes* and, 36
- exo*-Cellobiohydrolase, *Lentinus edodes* and, 36
- Cellobiohydrolases, in mushrooms, 10
- Cellulase
Lentinus edodes and, 36–57
 in mushrooms, 10
- Cellulase genes, in *Lentinus edodes*, 46
- Cellulose
 in biomass waste, 10
Lentinus edodes degradation of, 36, 60
 from mushrooms, 149
 in *Wolfiporia cocos* cultivation, 121
- Cellulose control, in vivo Ca/Mg absorption and, 131
- Cell walls
 in mushroom sclerotia, 121–122
 as source of antitumor polysaccharides, 149
- Center for Food Safety and Applied Nutrition (CFSAN), 203
 Office of Nutritional Products, Labeling, and Dietary Supplements, 205–206
- Cerebrospinal fluid (CSF), effects of lentinan on, 165
- Chang, Shu-Ting, xxi, 1, 27
- Chanterelles, 72
- Characteristics, for mushroom identification, 5
- Cheese, protein quality of, 88
- Chemical improvement, of antitumor polysaccharides, 176–177
- Chemical tests, in mushroom identification, 5
- Chemistry, in mushroom cultivation, 20
- Chemotaxis, GLP effects on, 164
- Chemotherapy, mushrooms and, 25
- Cheung, Peter C. K., xxi, xvii, 71, 111
- China
Agaricus brasiliensis cultivation in, 18
 food safety in, 215
Ganoderma lucidum cultivation in, 19
Lentinus edodes from, 35
 mushroom production in, 21
 mushroom sclerotia production in, 117
- mushroom species in, 1–2
Pleurotus tuber-regium consumption in, 118
Polyporus rhinocerus consumption in, 119
 total mushroom production in, 72–73
Volvariella cultivation in, 17–18
 wild and cultivated edible mushrooms from, 72, 73
Wolfiporia cocos consumption in, 120–121
- Chinese medicine
 mushroom uses in, 25, 147
 shiitake mushroom in, 215
- Chitin
 in cultivated mushroom dietary fiber, 77, 78
 dietary fiber and, 124, 125
 from mushrooms, 149
 in sclerotia, 124
 in sclerotial cell walls, 122
- Chitinase, *Lentinus edodes* and, 36
- Chitosan
 from mushrooms, 149
 in sclerotia, 124
- Chlorflavonin, biosynthesis of, 93–94
- Chlorophyll, as lacking in mushrooms, 10
- Cholesterol biosynthesis, mushrooms as reducing, 96–97
- Chromosomal DNA, in *Lentinus edodes* transformation, 57–58. See also Deoxyribonucleic acid (DNA)
- Chum, Winnie W. Y., xxi, 35
- Cinnamic acid, biosynthesis of, 93
- trans*-Cinnamic acid, as mushroom antioxidant, 92
- Citrate cycle, in *Lentinus edodes*, 48
- Citrate synthase, in *Lentinus edodes*, 48
- Citrinin, in mushrooms, 91–92
- Classical Chinese medicine, shiitake mushroom in, 215
- Classification, of edible mushrooms, 80
- Claviceps purpurea*, sclerotia of, 112
- Clones, in *Lentinus edodes* genetics, 52
- CMHAE carboxylated β -glucans, in chemical improvement of antitumor activity, 177
- Codex Alimentarius, on introducing medicinal-mushroom dietary supplements, 202–203
- Codex Alimentarius Commission, 202–203
 in nutritional evaluation, 87
- Codex Committee on Vegetable Proteins (CCVP), in nutritional evaluation, 87
- Cold shock, in *Lentinus edodes* primordium formation, 38
- Collybia confluens*, antitumor polysaccharide–protein complexes from, 158

- Collybia dryophila*, antitumor polysaccharides from, 154
- Collybia dryophila* polysaccharide (CDP), 164
- Collybia maculata*, antitumor polysaccharides from, 156
- Colonic fermentation, of dietary fiber, 129–131
- Colonic pH, in colonic fiber fermentation, 129–130
- Colony formation unit of granulocyte macrophages (CSU-GM), MBG treatment and, 170
- Color. *See also* Pigmentation; Pigments
in mushroom identification, 5
of *Polyporus rhinocerus*, 119
of sclerotial dietary fiber, 126
of *Wolfiporia cocos*, 120
- Color change
of cortex, 116
of rind, 116
- Column packing, in *Pleurotus* cultivation, 17
- Comfrey, safety of, 216
- Commercial-scale cultivation, of *Lentinus edodes*, 16
- Competitive microorganisms, in mushroom cultivation, 13
- Complementary DNA (cDNA), in *Lentinus edodes* genetics, 36, 43, 44. *See also* cDNA entries
- Complement receptor 3 (CR3), in immune response, 162
- Compost
for *Pleurotus tuber-regium*, 118–119
for *Polyporus rhinocerus*, 119–120
for *Wolfiporia cocos*, 121
- Compost preparation phase
for *Agaricus* mushrooms, 14
in mushroom cultivation, 12, 13
- Compost technology, mushrooms and, 8
- Conducting hyphae, during sclerotial development, 114
- Conformation, of antitumor polysaccharides, 175–176
- Congress, DSHEA and, 204
- Conservation, in mushroom cultivation, 21
- Copper
in cultivated mushrooms, 76
in vitro sclerotial binding of, 128–129
in sclerotial dietary fiber, 125
- Coprinaceae, classification of, 80
- Coprinopsis cinerea*, 44, 56. *See also* *Coprinus cinereus*
- Coprinus cinereus*, 57, 59. *See also* *Coprinopsis cinerea*
- Coprinus comatus*, 85
- chemical composition of, 82
- classification of, 80
- world production of, 73
- Cord blood (CB) cells, 170
- Cordyceps*, xvii
- Cordyceps ophioglossoides*, antitumor polysaccharide–protein complexes from, 158
- Cordyceps sinensis*
antiangiogenesis and, 172
antimetastatic effects of, 172
antitumor polysaccharides from, 154
FWE water extract from, 158, 171
hypolipidemic effects of, 95
- Cordyglucan, from mushrooms, 154
- Coriolus (Trametes) versicolor*. *See also* *Trametes versicolor*
antiangiogenesis and, 172
antimetastatic effects of, 171, 172
antitumor polysaccharide–protein complexes from, 158, 159–160
FWE water extract from, 158, 171
medicines from, 25
polysaccharides isolated from, 148, 150
PSK polysaccharide from, 166–167, 169–170
- Coriolus hirsutus*, 57, 59
- Cortex, structure of, 115, 116–117
- Cottage-scale cultivation, of *Lentinus edodes*, 16
- Council for Responsible Nutrition (CRN), 204
- Cristulariella*, during early sclerotial ontogeny, 115
- Crop frequency, in *Agaricus* cultivation, 14
- Cross breeding, of *Lentinus edodes*, 56, 57
- Crude protein
in conventional edible mushrooms, 74
in nonconventional edible mushrooms, 79
in sclerotia, 123–124
- CT-rich sequence element, in *Lentinus edodes* transcriptional regulation, 55–56
- Culinary–medicinal products, types of, 201
- Cultivated edible mushrooms, 72, 73. *See also* Edible mushrooms; Newly developed cultivated mushrooms
in mushroom industry, 2
species of, 71
world production of, 72–73
- Cultivation. *See also* Mushroom cultivation
of *Pleurotus tuber-regium*, 118–119
of *Polyporus rhinocerus*, 119–120
of sclerotia, 117–121
of *Wolfiporia cocos*, 121
- Cultivation substrate. *See also* Substrate entries
in *Agaricus brasiliensis* cultivation, 18–19

- in *Ganoderma lucidum* cultivation, 19–20
 in *Pleurotus* cultivation, 17
- Culture filtrates, of mushrooms, 149
- Culture media, in *Lentinus edodes* cultivation, 15
- Culturing, submerged, 219
- Curvulic acid, in mushrooms, 91, 92
- Cyclic adenosine monophosphate (cAMP), in
Lentinus edodes primordium formation, 38
- Cyclin B, in *Lentinus edodes* genetics, 52
- Cyclins, from mushrooms, 159, 161
- Cyclophosphamide (CP), 170–171
 immunomodulatory effects of, 164
- Cystathionine, mushroom-related
 hypocholesterolemia and, 94
- Cysteine
 in conventional edible mushrooms, 74, 75
 in mushroom protein, 88, 89
- Cytarabine, 160
- Cytochrome P450, *Lentinus edodes* and, 44
- Cytokine expression, mushroom polysaccharides
 and, 151
- Cytokine production, antitumor and
 immunomodulatory effects and, 132, 133
- Cytokines, 178
 AC-PS effects on, 168
 in angiogenesis, 172
 antimetastatic effects on, 171
 dendritic cells and, 168–169
 effects of lentinan on, 165
 effects of PG101 and, 165
 effects of PSK and, 167
 GLP effects on, 163
 in immune response, 162
 mushroom polysaccharide effects on,
 167–168
 polysaccharides and, 148
- Cytoplasm
 glycogen in hyphal, 122
 in rind cells, 116
- Cytoplasmic reserves, of sclerotia, 122–123
- Cytotoxicity, 178, 179
 as antitumor mechanism, 153, 159
 of polysaccharide–protein complexes,
 160–161
- Cytotoxic lymphocytes, in immune response,
 161–162
- Cytotoxic properties, of *Wolfiporia cocos*, 120
- Cytotoxic responses, polysaccharides and, 148,
 150
- Dampness, mushrooms and, 2–3
- Daniella oliveri*, as *Pleurotus tuber-regium*
 compost, 119
- Databases, in mushroom cultivation, 21
- Death, food safety and, 215–216. *See also*
 Apoptosis
- Dehydroepachymic acid, in *Wolfiporia cocos*
 cultivation, 121
- Dectin-1
 in immune response, 162
 in sclerotial antitumor and
 immunomodulatory studies, 133
- Dehydrogenases, in *Lentinus edodes*, 48, 53
- Dendritic cells (DCs)
 in immune response, 161–162
 mushroom polysaccharides and, 150, 163,
 168–170
 in sclerotial antitumor and
 immunomodulatory studies, 133
- Denmark, food safety systems in, 219–220
- Deoxyribonucleic acid (DNA). *See also*
 Complementary DNA (cDNA); DNA
 entries; Mitochondrial DNA (mtDNA)
 RFLPs; Recombinant DNA (rDNA)
 in *Lentinus edodes* particle bombardment
 transformation, 57–58
 in mushroom cultivation, 20
- Department of Food and Dietary Services
 (Israel), 214
- Department of Health and Human Services
 (DHHS), 208
- Descriptions, in mushroom identification, 6
- Desert truffle, 2
- Designer foods, regulation of, 200
- Deuteromycotina, sclerotia of, 112
- Developing countries
 mushroom harvests in, 22
 mushrooms in, 72
- Developmental structural proteins, in *Lentinus*
edodes, 48
- Development stage, of sclerotial ontogeny,
 113–114, 114–115
- D-fraction
 grifolan and, 165, 166
 immunomodulatory effects of, 167–168
 regulation of, 200
- Diabetes, 207
 edible mushrooms and, 71
 mushrooms in treatment of, 97–99
- Dictyophora indusiata*
 antioxidants in, 90
 antitumor polysaccharides from, 154, 156
 carbohydrate content of, 78
 dietary fiber in, 77
 fat content of, 75
 moisture content of, 74
- Dietary enrichment, via mushroom cultivation,
 21, 22, 23

- Dietary fiber (DF). *See* Fiber
- Dietary food supplements
 mushroom polysaccharides as, 147–148
 mushrooms as, 23, 24–25
- Dietary protein shortages, mushrooms as
 alleviating, 80
- Dietary Supplement and Nonprescription Drug
 Consumer Protection Act of 2006, 208
- Dietary Supplement Guide, 205–206
- Dietary supplement pyramid, 200
- Dietary supplements (DSs)
 in Australia and New Zealand, 211–212
 in Canada, 210–211
 in European Union, 208–210
 in Israel, 214–215
 in Japan, 212–214
 regulation of, 200–201
 safety and diversity of, 215–218
 US regulation of, 204–208
- Dietary Supplements Health and Education Act
 (DSHEA), 200, 204, 205
- Differential display, in *Lentinus edodes* genetics,
 51–52
- Differential gene expression, in *Lentinus edodes*,
 38
- Dihydrochalcone, biosynthesis of, 93–94
- Dikaryotic mycelia, of *Lentinus edodes*, 37,
 38–44
- Dimethyl sulfoxide (DMSO), 175
- Direct cytotoxicity, 179. *See also* Direct toxicity
 as antitumor mechanism, 153
- Directives, on European dietary supplements,
 209, 210
- Direct toxicity, of nutrients, 216–217. *See also*
 Direct cytotoxicity
- Disease, defined, 205
- Ditags, in *Lentinus edodes* genetics, 52
- Diversity, 220
 of dietary supplement types, 215–218
 of polysaccharides, 148
- DNA fingerprints, for *Lentinus edodes*, 49–50.
See also Deoxyribonucleic acid (DNA)
- DNA fragments, in *Lentinus edodes* sequencing
 by synthesis, 54–55
- DNA helicases, in *Lentinus edodes*, 46
- DNA microarray analysis, in *Lentinus edodes*
 genetics, 36, 51, 53–54, 61
- DNA synthesis, in *Lentinus edodes*, 45
- Dolichos lablab*, protein quality of, 88
- Dormancy, in sclerotial ontogeny, 114
- Dosages, WHO guidelines and, 202
- Dot-blot hybridization, in *Lentinus edodes*
 genetics, 54
- Doxorubicin (DOX), 157, 170
- DPPH radical scavenging, in mushroom
 antioxidant assays, 90
- Drug abuse, US regulations and, 208
- Drug approval, 218
- Drugs, safety of, 215
- Drug withdrawal, US regulations and, 208
- Dry matter (DM), in sclerotia, 123–124
- Dry mushrooms, moisture content of, 74
- Ecological classification, of mushrooms, 4, 5
- Ecology, mushrooms in, 9
- Economic importance, of mushrooms, 72, 73
- Edible mushrooms, 3, 4. *See also* Cultivated
 edible mushrooms; Wild edible entries
 classification of, 80
 distinguishing from poisonous, 6
 health benefits of, 71, 89–99
 international movement for, 26, 27
 in mushroom industry, 26
 nutritional composition of, 73–79, 81–87
 wild and cultivated, 72, 73
- Edible mycorrhizal mushrooms, international
 movement for, 27
- Egusi*, *Pleurotus tuber-regium* in, 118
- Ehrlich carcinoma, mushroom
 polysaccharide–protein complexes versus,
 160
- Elaeis guineensis*, as *Pleurotus tuber-regium*
 compost, 119
- Electroporation, for *Lentinus edodes*
 transformation, 58
- FLN3 protein, *Lentinus edodes* and, 44
- Emulsification, of sclerotial dietary fiber, 126
- Emulsifying activities (EA), of sclerotial dietary
 fiber, 126, 127–128
- Emulsion stability (ES), of sclerotial dietary
 fiber, 126, 128
- endo-cellobiohydrolase*, *Lentinus edodes* and, 3
- Endocytosis genes
 of *Lentinus edodes*, 42
 in *Lentinus edodes* yeast two-hybrid analysis,
 54
- Endogenous factors, during sclerotial ontogeny,
 113
- Endoglucanases, in mushrooms, 10
- Endoplasmic reticulum (ER), in rind cells, 116
- Energy
 from conventional edible mushrooms, 78
 from nonconventional edible mushrooms, 79
- Energy demand, in *Lentinus edodes*, 44
- Energy production, in *Lentinus edodes*, 47–48
- Energy production genes, of *Lentinus edodes*, 4
- Energy sources, in nutrition, 23

- Enokitake mushroom, hypocholesterolemic effects of, 97
- Environment
 applied mushroom biology and, 9, 11
 in mushroom identification, 5
 population growth and, 10, 28
- Environmental decontamination, via mushroom cultivation, 21
- Environmental shocks, in mushroom cultivation, 12
- Environmental technology, mushrooms and, 8
- Enzymatic pH-stat assays, in nutritional evaluation, 87
- Enzymes
 during early sclerotial ontogeny, 115
 of *Lentinus edodes*, 36–37
 in *Lentinus edodes* energy production, 48
 in *Lentinus edodes* screening, 52
 in *Lentinus edodes* SAGE and LongSAGE, 52–53
 in *Lentinus edodes* transformation, 57–58
 in *Lentinus edodes* wood degradation, 60
 in lignin degradation, 60
 in mushrooms, 10–11
 in sclerotial cell walls, 122
 in sclerotial dietary fiber preparation, 126
- Epigallocatechin 3-gallate, as mushroom antioxidant, 92
- EPSF (exopolysaccharide fraction)
 antiangiogenesis and, 172
 antimetastatic effects of, 172
- Equipment, in *Lentinus edodes* cultivation, 16
- Ergocalciferol, in cultivated mushrooms, 77
- Eritadenine
 hypocholesterolemic effects of, 94
 molecular structure of, 96
- Erythrocyte hemolysis, in mushroom antioxidant assays, 90
- Erythroleukemia, mushroom polysaccharides versus, 153
- Escherichia coli*, 57, 58
- Essence of Mushrooms capsules, FDA detention of, 206
- Essential amino acids, in conventional edible mushrooms, 74
- Essential nutrients, in mushroom cultivation, 13
- Eumycota, 119
- Europe. *See also* European Union
 introducing medicinal-mushroom dietary supplements in, 203
 mushroom nutraceutical regulation in, 201
 wild and cultivated edible mushrooms from, 72, 73
- European Commission (EC), quality standards of, 209
- European Community, 220
- European Court of Justice, on dietary supplements, 210
- European Food Supplements Directive, 203
- European Union, introducing medicinal-mushroom dietary supplements in, 208–210
- Eurotium chevalieri*, antioxidants in, 91, 92
- exg1* gene, in *Lentinus edodes*, 46
- exg* genes, in *Lentinus edodes*, 59
- exo*-cellobiohydrolase, *Lentinus edodes* and, 36
- Exogenous factors, during sclerotial ontogeny, 113
- Exopolymers, in mushroom-related hypoglycemia, 98, 99
- Exopolysaccharide (EPS), 151
- Experts, in mushroom identification, 6
- Expressed sequence tags (ESTs), in *Lentinus edodes* genetics, 36, 50, 51, 53, 54
- Ex situ conservation, in mushroom cultivation, 21
- Extracellular enzymes, of *Lentinus edodes*, 36–37
- Extracellular matrix
 interhyphal space and, 115
 of sclerotia, 122
- Extract of *Ganoderma lucidum* polysaccharide (EORP), AC-PS effects on, 168
- Exudation, during early sclerotial ontogeny, 115
- Fat(s)
 in conventional edible mushrooms, 75, 81
 in mushrooms, 23
 in nutrition, 23
- Fatty acid desaturases, in *Lentinus edodes*, 45
- Fatty acids
 in conventional edible mushrooms, 75, 80
 during early sclerotial ontogeny, 115
 in mushrooms, 24
- Federal Food, Drug, and Cosmetic Act, 204, 206, 208
- Federal Trade Commission (FTC), 203
- Fermentability, of sclerotia, 129–131
- Fermentation
 in *Agaricus* cultivation, 14
 in mushroom cultivation, 10–11
- Fermentation products, regulation of, 218
- Fermentation technology, mushrooms and, 8, 23
- Fiber
 in conventional edible mushrooms, 77–78
 hypocholesterolemic effects of, 96, 97
 of sclerotia, 124–126

- Fiber-optic slides, in *Lentinus edodes*
sequencing by synthesis, 55
- Fiber supplements, sclerotia and, 124, 125
- FIBRAPLAN dietary fiber supplement, sclerotia
and, 125
- FIBREX dietary fiber supplement, 127–128
- Fibrosarcoma
mushroom polysaccharides versus, 153
polysaccharide–protein complexes versus,
160, 167
- Filamentous fungi
medicinal value of, 149
structure of, 111–112
- Fingerprinting, of *Lentinus edodes*, 50
- First International Conference on Mushroom
Science, 26
- Flammulina*, world production of, 72, 73
- Flammulina velutipes*, 58, 85
antioxidants in, 90
antitumor polysaccharide–protein complexes
from, 158
antitumor polysaccharides from, 154, 155, 156
chemical composition of, 82
classification of, 80
hypocholesterolemic effects of, 97
hypolipidemic effects of, 95
moisture content of, 73
polysaccharides isolated from, 153
- Flavoglucanin, as mushroom antioxidant, 91, 92
- Flavonoids
biosynthesis of, 93
in cultivated mushrooms, 78
- Flavor 5'-nucleotides, in cultivated mushrooms,
78–79
- Flavorful production genes, of *Lentinus edodes*,
42
- Flow cytometric analysis, in sclerotial antitumor
and immunomodulatory studies, 132
- Folates, in cultivated mushrooms, 76
- Folic acid, adverse effects of, 217
- Fomes fomentarius*, antitumor
polysaccharide–protein complexes from,
158
- Fomitella fraxinea*
antitumor polysaccharide–protein complexes
from, 158
antitumor polysaccharides from, 155, 156
- Food. *See also* Designer foods; Functional
foods; Medical foods; Novel foods
applied mushroom biology and, 8–9
mushrooms as, xvii, 1–34, 72
natural and organic in US, 203
population growth and, 10, 28
sclerotia as, 111–146
- Food Act of 1981 (New Zealand), 201
- Food Additive Amendments (1958), 204
- Food additives, US regulation of, 204
- Food and Agricultural Organization (FAO),
202–204, 214–215
on mushroom protein and amino acid content,
74, 75
- Food and Drug Administration (FDA)
European Union and, 209
food regulation by, 203–204, 204–208, 218
medical food regulation by, 200
- Food fortification policy, in Canada, 210–211
- Food industry, mushrooms in, 10–11
- Food processing industry, biomass waste from,
10–11
- Food products, desirability of, 24
- Food safety systems, 219–220
- Foods for Particular Nutritional Uses
(PARNUTS), 208
- Foods for Special Dietary Uses (FOSDU), in
Japan, 214
- Foods for specified health uses (FOSHU), in
Japan, 212–214
- Food supplements
European Union regulation of, 209
mushrooms as, 23, 24–25
- Foods with nutrient function claims (FNFC), in
Japan, 213
- Food with health claims (FHC), in Japan, 212
- Forestry
biomass waste from, 10–11
Ganoderma lucidum cultivation and, 19–20
- Forests, applied mushroom biology and, 9
- Formylmethylation, in chemical improvement of
antitumor activity, 176
- Free amino acids, in conventional edible
mushrooms, 74–75
- Free radicals
lignin degradation by, 60
mushrooms and, 24
mushroom scavenging of, 89–90
- Fruiting bodies, 178, 219
antitumor polysaccharides from, 152, 153
in human diet, 72
of *Lentinus edodes*, 36, 38–44, 44–47
medicinal value of, 149
mushroom nutraceuticals from, 24–25
in mushroom-related hypoglycemia, 98, 99
of *Pleurotus tuber-regium*, 118
SAGE profiles of *Lentinus edodes*, 53
of *Wolfiporia cocos*, 120
- Fruiting body morphogenesis, in *Lentinus
edodes*, 46
- Fruiting body senescence, in *Lentinus edodes*, 59

- Fruiting culture
 of *Lentinus edodes*, 14, 15, 16
 in mushroom cultivation, 13
 preparation of, 13–14
- Fruiting cycle, of *Lentinus edodes*, 37–38
- Fruiting growth phase, in mushroom cultivation, 11–12
- Fruiting management phase, in mushroom cultivation, 12, 13
- Fucogalactan
 antitumor effects of, 166
 from mushrooms, 156, 157
- Fucoglucomannan, from mushrooms, 156
- Fu ling mushroom, 120
- Functional foods
 in Canada, 210
 FDA on, 208
 mushrooms as, xvii, 1–34
 regulation of, 200
- Functional genomics studies, transformation in, 56, 57
- Fungal histidine kinase, in *Lentinus edodes*, 47
- Fungal hyphae, 80
- Fungal protein, from mushrooms, 11
- Fungi. *See also* Wood rot fungus
 biology of, 6–7
 biosynthesis of phenolic compounds by, 93–94
 cell walls of, 121–122
 identification of, 4–5
 Israeli regulation of, 214–215
 molecular chaperones in, 59–60
 mushrooms as, 2–3, 3–4, 10–11, 149
 phenolic antioxidants in, 91–93
 structure of filamentous, 111–112
- Fungisterol, as mushroom antioxidant, 92
- FWE water extract
 AC-PS effects on, 168
 antimetastatic effects of, 172
- FYBOGEL dietary fiber supplement, sclerotia and, 125
- Galactan, in sclerotial dietary fiber, 125
- Galactoglucomannan, from mushrooms, 157
- Galactomannan
 antitumor effects of, 166
 from mushrooms, 156
- Galactomannan–protein complexes, 149
- Galactomannoglucan, from mushrooms, 155, 156
- Galactose
 in cultivated mushroom dietary fiber, 78
 in sclerotial dietary fiber, 125
- Galactoxyloglucan, from mushrooms, 155
- Gallic acid, biosynthesis of, 93
- γ -amino butyric acid (GABA), in conventional edible mushrooms, 74
- Ganoderan, from mushrooms, 154
- Ganoderma*, xvii
 ecological classification of, 5
 polysaccharides isolated from, 151–152
 as saprophytes, 4
- Ganoderma applanatum*, polysaccharides isolated from, 151, 152
- Ganoderma capense*, polysaccharides isolated from, 151
- Ganoderma lucidum*
 antiangiogenesis and, 172–173
 antimetastatic effects of, 172
 antitumor polysaccharide–protein complexes from, 158, 162–163
 antitumor polysaccharides from, 154, 155
 cultivation of, 19–19
 ecological classification of, 5
 FWE water extract from, 158, 172
 ganopoly from, 168
 hypolipidemic effects of, 95
 medicinal applications of, 4
 medicinal effects of, 24
 medicines from, 25
 polysaccharides isolated from, 151, 152, 169
 as saprophyte, 4
- Ganoderma lucidum* polysaccharide (GLP), 163–163
 in immune response, 162–163
- Ganoderma tsugae*
 antitumor polysaccharide–protein complexes from, 158
 antitumor polysaccharides from, 154, 155, 156
 molecular mass of polysaccharides from, 174
 polysaccharides isolated from, 151, 152
- Ganopoly, 151
 immunomodulatory effects of, 168
- Garden of Life RM-10, FDA detention of, 207–208
- Garnishes, mushrooms as, 72
- Gas chromatography–mass spectrometry (GC-MS), in antioxidant assays, 92
- Gaseous exchange, in mushroom cultivation, 13
- Gastrointestinal tract, in vitro sclerotial binding of minerals in, 128–129
- GC box, in *Lentinus edodes* transcriptional regulation, 55–56
- Gelling, of sclerotial dietary fiber, 126
- Gene combinations, in mushroom cultivation, 20
- Gene expression, 178
- Gene expression analysis, of *Lentinus edodes*, 50–55

- General Accounting Office (GAO), on food safety systems, 219–220
- “Generally recognized as safe” (GRAS) criteria, 204, 207
- Genes
- of *Lentinus edodes*, 36–48
 - in *Lentinus edodes* development, 48
 - in *Lentinus edodes* energy production, 47–48
 - for *Lentinus edodes* mature fruiting body formation, 44–47
 - in *Lentinus edodes* signal transduction, 47, 61
 - in *Lentinus edodes* sequencing by synthesis, 55
 - in *Lentinus edodes* transformation, 58–59
- Genetic mapping, of *Lentinus edodes*, 50
- Genome Sequencer 20 system, in *Lentinus edodes* sequencing by synthesis, 55
- Genome sequencing, in *Lentinus edodes* sequencing by synthesis, 55
- Germany
- food safety systems in, 219–220
 - regulation of dietary supplements in, 210
- Germination, in sclerotial ontogeny, 114
- Germplasm, in mushroom cultivation, 20–21
- Germplasm databases, in mushroom cultivation, 21
- GFPS1b polysaccharide, isolation of, 150
- Gill development, in *Lentinus edodes*, 44–47
- Gills
- of *Lentinus edodes*, 38
 - in mushroom identification, 5
- GK16 mushroom, 85
- chemical composition of, 82
- GI-PP (*Ganoderma lucidum* polysaccharide peptide), in angiogenesis, 172–173
- Glucanase activity, in *Lentinus edodes*, 59
- Glucanase-encoding gene, in *Lentinus edodes*, 46
- Glucan–protein complexes
- from mushrooms, 158, 159
 - structure and antitumor activity of, 173–174
- Glucans. *See also* α -glucans; β -glucans
- antitumor mechanisms of, 153–157
 - branching configurations of, 175
 - from mushrooms, 149
 - sclerotial extracellular matrix and, 122
- Glucoamylase, *Lentinus edodes* and, 36–57
- Glucogalactan–protein complex, from mushrooms, 158
- Glucogalactans, from mushrooms, 152, 156
- Glucokinase, mushroom-related hypoglycemia and, 98–99
- Glucomannan, from mushrooms, 156
- Glucopyranan, from mushrooms, 157
- Glucopyranosyl residue, mushroom-related hypoglycemia and, 98
- Glucosamine, in sclerotial dietary fiber, 125
- Glucose
- colonic fermentation and, 130
 - in cultivated mushrooms, 78
 - in cultivated mushroom dietary fiber, 77–78
 - during early sclerotial ontogeny, 115
 - mushroom-related hypoglycemia and, 98
- Glucose-6-phosphate dehydrogenase, mushroom-related hypoglycemia and, 98–99
- Glucose-based oligosaccharides (GOSs), in vivo Ca/Mg absorption and, 132
- Glucose-based polysaccharides, dietary fiber and, 124
- Glucose residues, in sclerotial dietary fiber, 125
- Glucosidases, *Lentinus edodes* and, 36
- β -Glucosidases, in mushrooms, 10
- Glucoxylan, from mushrooms, 152, 156
- Glucurumannan–protein complexes, 149
- Glucuronic acids, in sclerotial dietary fiber, 125
- Glucuronoglycan, 151
- Glucuronoxylomannan
- in cultivated mushroom dietary fiber, 78
 - from mushrooms, 157
- Glucuropyranosyluronic residues, mushroom-related hypoglycemia and, 98
- Glutamic acid, in conventional edible mushrooms, 74
- Glyceraldehyde-3-phosphate dehydrogenase (GPD), in PEG-mediated *Lentinus edodes* 58. *See also* GPD entries
- Glycine, in conventional edible mushrooms, 75
- Glycogen
- in cultivated mushrooms, 78
 - in sclerotial cytoplasmic reserves, 122
 - during sclerotial development, 114
- Glycolysis, in *Lentinus edodes*, 48
- Glycosidic linkages, in polysaccharides, 148
- GM-CSF (granulocyte macrophage colony-stimulating factor), 164, 178. *See also* Granulocyte colony-stimulating factor (G-CSF); Macrophage colony-stimulating factor (M-CSF)
- effects of PG101 and, 165
- Good agriculture practice (GAP), 217
- Good clinical practice (GCP), 218
- Good laboratory practice (GLP), 217
- Good manufacturing practice (GMP), 217
- WHO guidelines and, 202
- Good production practice (GPP), 218

- GPD gene, in *Lentinus edodes* transformation, 58. *See also* Glyceraldehyde-3-phosphate dehydrogenase (GPD)
- GPD promoter and terminator, in *Lentinus edodes* transformation, 57, 58
- Granular glycogen deposits, in sclerotial cytoplasmic reserves, 122
- Granulocyte colony-stimulating factor (G-CSF), 170. *See also* GM-CSF (granulocyte macrophage colony-stimulating factor)
- Granulocytes
 PG101 treatment and, 170
 SCG and, 170–171
- Greenhouse gases, population growth and, 10
- Grey oyster mushroom, 17. *See also* *Pleurotus sajor-caju*
- Grifola frondosa*, 85. *See also* Maitake mushroom
 antioxidants in, 90
 antitumor glucans from, 157, 165–166
 antitumor polysaccharide–protein complexes from, 158
 antitumor polysaccharides from, 154, 155, 156
 carbohydrate content of, 78
 chemical composition of, 82
 chemical improvement of antitumor polysaccharides from, 176
 classification of, 80
 D-fraction from, 167–168
 fat content of, 75
 heteroglycan–protein complex from, 167
 hypocholesterolemic effects of, 97
 hypolipidemic effects of, 95
 Japanese production of, 72–73
 MBG from, 170
 moisture content of, 73
 molecular mass of polysaccharides from, 174
 mushroom-related hypoglycemia and, 98
 polysaccharides isolated from, 148, 150
 regulation of polysaccharides from, 199–200
- Grifolan, antitumor effects of, 165–166
- Grifola umbellata*
 antitumor polysaccharides from, 154
 cultivation of sclerotia of, 117
- Growth genes, of *Lentinus edodes*, 36–37, 39–42
- Guanidine, mushroom-related hypoglycemia and, 99
- Guanidinoacetic acid, mushroom-related hypocholesterolemia and, 94
- Guanosine monophosphate (GMP), in cultivated mushrooms, 78
- Guidance for Industry: Botanical Drug Products* (FDA), 218
- Guidelines for the Assessment of Herbal Medicine* (WHO), 202
- Guidelines for the Safety Assessment of Novel Foods Derived from Plants and Microorganisms, 211
- Haploid monokaryotic mycelia, of *Lentinus edodes*, 38
- Harvesting phase, in mushroom cultivation, 12, 13
- HDL cholesterol levels, 97
- Health, applied mushroom biology and, 8–9
- Health benefits
 of edible mushrooms, 89–99
 of mushrooms, 71–109
- Health Canada, 210–211
- Health claims, 206
 in Japan, 214
- Health Food Emporium, FDA detention of, 207–208
- Health Promotion Law, in Japan, 214
- Heat shock proteins (HSPs), as molecular chaperones, 59
- Heavy metals
 in cultivated mushrooms, 76
 in nonconventional edible mushrooms, 79
- Hebeloma crustuliniforme*, antitumor polysaccharide–protein complexes from, 158
- Helicases, in *Lentinus edodes*, 46
- Helper T cells, effects of lentinan on, 165
- Hematopoietic stem cells, mushroom polysaccharide effects on, 170–171
- Hemicelluloses
 in biomass waste, 10
 in cultivated mushroom dietary fiber, 78
Lentinus edodes degradation of, 36
 in *Wolfiporia cocos* cultivation, 121
- Hepatic cholesterol, mushroom effects on, 97
- Hepatic glucose, colonic fermentation and, 130
- Hepatic HMG-CoA reductase, 97
- Herbal medicines, WHO guidelines and, 202
- Herbal substances, European Union regulation of, 209
- Herbs, in dietary supplements, 200
- Hericium erinaceus*, 86
 antioxidants in, 90
 antitumor polysaccharides from, 154, 155, 156
 ash and mineral content of, 76
 chemical composition of, 82
 classification of, 80
 mushroom-related hypoglycemia and, 98
 world production of, 73

- Hericium ramosum*, 86
 chemical composition of, 82
 classification of, 80
- Heterogalactan, from mushrooms, 156, 157
- Heteroglucans, from mushrooms, 155–156
- Heteroglycan–protein complexes
 immunomodulatory effects of, 167
 from mushrooms, 158, 159
 structure and antitumor activity of, 173–174
- Heteroglycans, from mushrooms, 149, 156–157
- Heteropolysaccharide–protein complexes, from mushrooms, 160–161
- Heteroposaccharides, from mushrooms, 152
- Hexokinase, mushroom-related hypoglycemia and, 98–99
- High density lipoprotein (HDL), 97
- High-throughput sequencing technologies, in *Lentinus edodes* sequencing by synthesis, 54–55
- Histidine
 in conventional edible mushrooms, 75
 in mushroom protein, 89
- Histidine kinase, in *Lentinus edodes*, 47
- Hoelen mushroom, 120
- Hohenbuehelia serotina*, antitumor polysaccharides from, 156
- Homeostasis, polysaccharides and, 148
- Homobasidiomycetes, 35
- Homocysteine, mushroom-related hypocholesterolemia and, 94
- Homoglucans, from mushrooms, 154–155
- Hong Kong, 206
 mushroom conference in, 27
- Host-specific factors, in colonic fiber fermentation, 129
- hph* gene, in PEG-mediated *Lentinus edodes* transformation, 56
- HRA cell proliferation, mushroom polysaccharides versus, 151
- HSP70 protein, as molecular chaperone, 59
- HUMAMIL dietary fiber supplement, sclerotia and, 125
- Human fecal microflora, colonic fermentation and, 130
- Human immunodeficiency virus (HIV), mushrooms and, 21–22
- Human peripheral blood mononuclear cells (hPBMCs), effects of PG101 and, 165
- Humans
 applied mushroom biology and, 8–9
 benefits of mushrooms for, 71
 feeding, 23
 health benefits of mushrooms to, 89–99
 mushrooms in diet of, 72
- Human tumor xenografts, in sclerotial antitumor and immunomodulatory studies, 133–134
- Human umbilical vein endothelial cells (HUVECs), antiangiogenesis and, 172–173
- Human welfare, mushrooms and, 28–29
- Hungary, mushroom production in, 21
- Hurulingzhi mushroom, 119
- HWE heteropolysaccharide–protein complex, 157–159, 161
- Hybridization, in *Lentinus edodes* genetics, 54
- Hybridization analysis, *Lentinus edodes* meiosis and, 61
- Hydnaceae, classification of, 80
- Hydration properties, of sclerotial dietary fiber, 127
- Hydrogen peroxide, lignin degradation by, 60
- Hydrophobins, of *Lentinus edodes*, 44, 48, 53
- Hydroxybenzoic acid, as mushroom antioxidant, 92
- p*-Hydroxybenzoic acid, biosynthesis of, 93
- Hydroxylation, in chemical improvement of antitumor activity, 176
- Hydroxyl free radicals, mushroom scavenging of, 89–90
- 4-Hydroxymethylbenzenediazonium (HMBD), US regulation of, 204
- Hygromycin B phosphotransferase gene, in *Lentinus edodes* transformation, 58
- Hygromycin B resistance, *Lentinus edodes* transformation and, 58
- Hymenium, in *Lentinus edodes*, 45
- Hymenomycetes, 119
 classification of, 80
- Hymenophore, *Lentinus edodes* meiosis and, 60–61
- Hypercholesterolemia, mushrooms versus, 94
- Hyperglycemia, mushrooms in treatment of, 97–99
- Hyperhomocysteinemic effects, mushroom-related hypocholesterolemia and, 94
- Hyphae
 cell walls of, 121–122
 of cortex, 117
 of filamentous fungi, 111–112
 of medulla, 117
 polyphosphate granules in, 123
 of rind, 116
 during sclerotial ontogeny, 113–114
 structure of, 115
- Hypal cells, of rind, 116
- Hypal tips
 during early sclerotial ontogeny, 115
 rind and, 115–116
 structure of, 115

- Hypocholesterolemia
 colonic fermentation and, 130
 from mushrooms, 94–97
- Hypoglycemia, from mushrooms, 97–99
- Hypolipidemia, from mushrooms, 94, 95, 96
- Hypsizygus marmoreus*, 86
 antioxidants in, 90
 antitumor polysaccharides from, 154, 156
 chemical composition of, 82
 classification of, 80
 Japanese production of, 72–73
- Identification, of mushrooms, 4–6
- IL-12 interleukin, 162. *See also* Interleukins (ILs)
- IL-12p35 interleukin, 163
- IL-12p70 interleukin, 151
- Immune response, cancer and, 161–162
- Immunomodulation, as antitumor mechanism, 153, 161–171
- Immunomodulators, 161
- Immunomodulatory effects
 of mushroom polysaccharides, 147–198
 of sclerotia, 132–134
 of *Wolfiporia cocos*, 120
- Immunomodulatory proteins, in mushrooms, 25
- Immunopotentiators, mushroom products as, 200–201
- Incubation
 in *Lentinus edodes* cultivation, 16
 in *Pleurotus* cultivation, 17
- India
 mushroom nutraceutical regulation in, 201
 mushroom production in, 21
- Indoor fermentation, in *Agaricus* cultivation, 14
- Inducible nitric oxide synthase (iNOS) protein, 164
- Information, in mushroom cultivation, 20, 21
- Infrared (IR) spectrometry, in antioxidant assays, 92
- Ingredients
 labeling of, 204–205
 WHO guidelines and, 202
- Inhibitor of kappa B (I- κ B) kinase, dendritic cells and, 169
- Initials, in sclerotial ontogeny, 113–114
- Initiation stage, of sclerotial ontogeny, 113
- Innate immunity, cancer and, 161–162
- Innovation, in mushroom industry, 22
- Inonotus obliquus*
 antitumor polysaccharides from, 156
 endopolysaccharide from, 166
 regulation of polysaccharides from, 199–200
- Inorganic compounds, in nutrition, 23
- Inosine monophosphate (IMP), in cultivated mushrooms, 78
- Inositol
 in cultivated mushrooms, 78
 during early sclerotial ontogeny, 115
- Insets, inside mushrooms, 2
- In situ conservation, in mushroom cultivation, 21
- Insoluble dietary fiber (IDF)
 in cultivated mushrooms, 77, 81
 of sclerotia, 124, 125
- Insulin-dependent diabetes mellitus (IDDM), mushroom-related hypoglycemia and, 98–99
- Insulin release, mushroom-related hypoglycemia and, 99
- Intercellular adhesion molecule-1 (ICAM-1), in immune response, 162, 179
- Interferon gamma (IFN- γ), 151, 162, 163, 164, 178
 effects of lentinan on, 165
- Interhyphal materials, in sclerotial ontogeny, 114
- Interhyphal space
 of medulla, 117
 sclerotial extracellular matrix and, 122
 structure of, 115
- Interleukins (ILs). *See also* IL-12 entries
 effects of lentinan on, 165
 effects of PG101 and, 165
 effects of PSK and, 167
 GLP effects on, 164
 grifolan and, 165
- Internal morphogenetic factors, during sclerotial ontogeny, 113
- International Commission on Mushroom Science, formation of, 26
- International Conference on Mycorrhizas, 27
- International Conference for Mushroom Biology and Mushroom Products (ICMBMP), 27
- International Journal of Medicinal Mushrooms (IJMM)*, 27
- International Medicinal Mushroom Conference (IMMC), 27
- International Society of Mushroom Science (ISMS), 21
 formation of, 26
- International Workshop on Edible Mycorrhizal Mushrooms (IW-EMM), 21, 27
- InterBsimple sequence repeat markers (ISSRs), for *Lentinus edodes*, 48, 49–50
- Inulin, in vivo Ca/Mg absorption and, 131
- Investigational new drug (IND), 218
- In vitro fermentability, of sclerotia, 129–131
- In vitro methods, in nutritional evaluation, 87

- In vitro mineral binding capacity, of sclerotia, 128–129
- In vitro protein digestibility (IVPD), in nutritional evaluation, 87, 88
- In vivo calcium absorption, by sclerotia, 131–132
- In vivo magnesium absorption, by sclerotia, 131–132
- Ireland, food safety systems in, 219–220
- Iron
 in cultivated mushrooms, 76
 in vitro sclerotial binding of, 128–129
 in mushrooms, 23
 in sclerotial dietary fiber, 125
- Iron sulfur protein (Ip) subunit gene, in *Lentinus edodes* transformation, 58
- Isoleucine
 in conventional edible mushrooms, 74, 75
 in mushroom protein, 89
- Israel, 220
 introducing medicinal-mushroom dietary supplements in, 214–215
- Japan, 207, 220
Agaricus brasiliensis cultivation in, 18
 introducing medicinal-mushroom dietary supplements in, 212–214
Lentinus edodes from, 35
 medicinal mushroom uses in, 25
 medicinal uses of mushroom polysaccharides in, 147
 mushroom antioxidant studies in, 89
 mushroom nutraceutical regulation in, 201
 mushroom-related hypocholesterolemia studies in, 94
 wild and cultivated edible mushrooms from, 72, 73
- Jaundice, *Wolfiporia cocos* in, 120
- Jew's ear mushroom, hypocholesterolemic effects of, 97. *See also* *Auricularia auricula-judae*
- Karyogamy, of *Lentinus edodes*, 38
- Kava
 for mushroom identification, 5, 6
 warnings against, 209
- Korea, medicinal uses of mushroom polysaccharides in, 147
- Krestin. *See also* PSK polysaccharide–protein complex
 from mushrooms, 25, 150
 regulation of, 200
- Kugitake mushrooms, antioxidants in, 89
- Kwan, Hoi-Shan, xxi, 35
- Labeling
 of Canadian dietary supplements, 210
 false or misleading, 206–208
 US regulation of, 203–204, 204–205
- Laccase, in mushrooms, 10
- Laccase genes, in *Lentinus edodes*, 46
- lac* genes, in *Lentinus edodes*, 46, 60
- Lactobacillus*, in colonic fiber fermentation, 130
- Laetiporus sulphureus*, antitumor polysaccharide–protein complexes from, 158
- Laminarinase, *Lentinus edodes* and, 36
- Lampteromyces japonicus*, antitumor polysaccharides from, 156
- Lateral development, of sclerotia, 113
- Latin America, mushroom production in, 22, 23, 73
- LDL cholesterol levels, mushrooms reducing, 97. *See also* Low density lipoprotein (LDL) oxidation
- Lead, in cultivated mushrooms, 76
- Le-cdc5* gene, in *Lentinus edodes* transcriptional regulation, 55
- Le.CDC5* protein, of *Lentinus edodes*, 43
- LeC1b* gene, of *Lentinus edodes*, 43
- Lectins, mushroom-related hypoglycemia and, 99
- Le.cyp* genes, of *Lentinus edodes*, 44
- Le.DRMIP* gene
 in *Lentinus edodes*, 43, 47
 in *Lentinus edodes* yeast two-hybrid analysis, 54
- Le.egl1* gene, in *Lentinus edodes*, 60
- Le.-FAD* genes, of *Lentinus edodes*, 44, 45
- Le.-FDA1* gene, of *Lentinus edodes*, 44
- Le.Ga* gene, in *Lentinus edodes*, 47
- Legal issues, in introducing medicinal-mushroom dietary supplements, 202–215
- Legumes, protein quality of, 88
- Le.hyd* genes, in *Lentinus edodes*, 48
- Le.MAPK* gene
 in *Lentinus edodes*, 43, 44, 47
 in *Lentinus edodes* yeast two-hybrid analysis, 54
- Le.mfbC* gene, in *Lentinus edodes*, 47
- LeMPP* gene, in *Lentinus edodes*, 48
- Le.nik1* gene
 in *Lentinus edodes*, 47
 in *Lentinus edodes* yeast two-hybrid analysis, 54
- LeNot1* gene, of *Lentinus edodes*, 43
- Lentinacin (lentysine), hypocholesterolemic effects of, 94

- Lentinan
 antitumor mechanism of, 153–157
 branching configuration of, 174–175
 conformation of, 175
 immunomodulatory effects of, 164–165
 isolation of, 148, 150
 from mushrooms, 25, 154, 161–162
 regulation of, 199–200
- Lentinan degradation, *Lentinus edodes* and, 59
- Lentinan degradation genes, of *Lentinus edodes*, 40
- Lentinula*, 35
- Lentinula edodes*. See *Lentinus edodes*
- Lentinus*
 hypocholesterolemic effects of, 94
 world production of, 72
- Lentinus edodes*, 35–69, 165. See also Shiitake mushroom
 anatomy of, 3
 antimetastatic effects of, 171, 172
 antioxidants in, 90, 91, 92
 antitumor polysaccharide–protein complexes from, 158
 antitumor polysaccharides from, 154, 156
 ash and mineral content of, 76
 biology and genetics of, 14, 15
 carbohydrate content of, 78
 chemical improvement of antitumor polysaccharides from, 176–177
 Chinese production of, 73
 classification of, 80
 conformation of polysaccharides from, 175–176
 cultivation of, 14–16
 development of, 37–47
 dietary fiber in, 77
 economic value of, 35–36
 fat content of, 75
 FWE water extract from, 158, 171
 gene expression analysis of, 50–55
 genetically improving, 35–36
 growth genes of, 36–37, 39–42
 hypocholesterolemic effects of, 94
 isolation of genes of, 36–48
 life cycle of, 14–15, 37–38
 lignocellulolytic enzymes of, 10
 medicinal value of, 25, 35
 moisture content of, 73
 molecular genetics of, 36, 48–50
 molecular mass of polysaccharides from, 174
 physiological processes in, 47–48, 61
 polysaccharides isolated from, 148, 149, 150
 process analysis of, 59–61
 protein and amino acid content of, 74, 75
 protein quality of, 88
 provenance of, 35
 regulation of polysaccharides from, 199–200
 taxonomy of, 35
 transcriptional regulation of, 55–56
 transformation of, 56–59
 vitamin content of, 76–77
 as wood rot fungus, 15
 world production of, 72, 73
- Lentinus giganteus*, 86
 chemical composition of, 82
 classification of, 80
- Lentinus lepideus*
 biosynthesis of phenolic compounds by, 93
 polysaccharide extracted from, 165, 170
- Lepiota*, toxicity of, 6
- Lepista nuda*, world production of, 73
- LePriA* gene, in *Lentinus edodes* transcriptional regulation, 55
- Le.ras* gene, in *Lentinus edodes*, 44, 47
- Le.recQ* gene, in *Lentinus edodes*, 46, 47
- Le.rnr2e* gene
 in *Lentinus edodes*, 45
 in *Lentinus edodes* meiosis, 60–61
- Leucine, in conventional edible mushrooms, 74, 75
- Leucopaxillus giganteus*, antitumor polysaccharides from, 156
- Leukemic cells, mushroom polysaccharide–protein complexes versus, 159–160, 161
- Lewis lung cancer, mushroom polysaccharides versus, 151–152
- Life cycles
 of *Lentinus edodes*, 37–38
 of mushrooms, 149
- Life expectancy, food safety and, 215
- Life-span increases, mushrooms and, 25
- Lignin
 in biomass waste, 10
 in cultivated mushrooms, 77, 78
Lentinus edodes degradation of, 36, 60, 61
- Ligninases, in mushrooms, 10
- Lignin peroxidase, from *Lentinus edodes*, 60
- Lignocellulolytic enzymes
 of *Lentinus edodes*, 36
 in mushrooms, 10
- Lignocellulose degradation, by *Lentinus edodes*, 60
- Lignocellulosic biomass waste, applied mushroom biology and, 9, 10–11, 21, 28
- Lignolytic system, of *Lentinus edodes*, 36
- Lignosus rhinoceros*, 119. See also *Polyporus rhinoceros*

- Linoleic acid**
 in conventional edible mushrooms, 75
 mushroom-related hypocholesterolemia and, 94
- Linolenic acid**, in conventional edible mushrooms, 75
- Lipid biosynthesis**, in *Lentinus edodes*, 45
- Lipid bodies**, in sclerotia, 123
- Lipid metabolism**, mushroom-related hypocholesterolemia and, 94
- Lipid peroxidation inhibition**, by mushrooms, 91
- Lipids**
 in conventional edible mushrooms, 75
 in mushrooms, 24
 in nonconventional edible mushrooms, 79
 in sclerotia, 123
 in sclerotial cytoplasmic reserves, 122, 123
- Liquid chromatography–mass spectrometry (LC-MS)**, in antioxidant assays, 92
- Liver injury**, from kava, 209
- Log cultivation**, of *Ganoderma lucidum*, 19–20
- LongSAGE**, in *Lentinus edodes* genetics, 52–53.
See also Serial analysis of gene expression (SAGE)
- Loose development**, of sclerotia, 113
- Lovastatin**
 hypocholesterolemic effects of, 96
 submerged culturing of, 219
- Low density lipoprotein (LDL) oxidation**. *See also* LDL cholesterol levels
 hypercholesterolemia and, 94
 hypocholesterolemia and, 97
 in mushroom antioxidant assays, 90
- LPK15 mushroom**, 86
 chemical composition of, 82
- Luciferase expression**, 166
- Lung cancer**
 GLP effects on, 163
 mushroom polysaccharides versus, 151–152
- Lung cancer cells**, antitumor polysaccharides versus, 157
- Lymphocytes**
 AC-PS effects on, 168
 in immune response, 161–162
 mushroom polysaccharide effects on, 163
- Lymphoma**, mushroom polysaccharide–protein complexes versus, 159–160
- Lyophyllum decastes*
 antitumor polysaccharides from, 154, 164
 polysaccharides isolated from, 153
- Lyophyllum ulmarium*
 dietary fiber in, 77
 fat content of, 75
 protein and amino acid content of, 75
- Lysine**
 in conventional edible mushrooms, 74, 75
 in mushroom protein, 88
- LZE extract**, 151
- Lzps-1**, 151–152
- Macrofungi**, mushrooms as, 2, 3, 149
- Macromolecules**, polysaccharides as, 148
- Macrophage colony-stimulating factor (M-CSF)**, 151. *See also* GM-CSF (granulocyte macrophage colony-stimulating factor)
- Macrophages**, 178
 in chemical improvement of antitumor activity, 176
 D-fraction and, 167–168
 galactomannan and, 166
 grifolan and, 165–166
 in immune response, 161–162, 162–163
 mushroom polysaccharides and, 150, 151, 159, 160, 163–167
 schizophyllan and, 165
 in sclerotial antitumor and immunomodulatory studies, 133
- Magnesium**
 in cultivated mushrooms, 76
 in vitro sclerotial binding of, 128–129
 in nonconventional edible mushrooms, 79
 in sclerotial dietary fiber, 125
- Magnesium absorption**, by sclerotia, 131–132
- Maitake D-fraction**. *See* D-fraction
- Maitake mushroom**, 207. *See also* *Grifola frondosa*
 antioxidants in, 89
 antitumor glucans from, 157
 antitumor polysaccharides from, 150
 hypocholesterolemic effects of, 97
- Manganese**
 in cultivated mushrooms, 76
 in *Lentinus edodes* cellulose degradation, 60
- Manganese peroxidase**, in mushrooms, 10
- Manna**, from mushrooms, 2, 156
- Mannans**
 in cultivated mushroom dietary fiber, 77
 in sclerotial dietary fiber, 125
- Mannitol**
 in cultivated mushrooms, 78
 during sclerotial development, 114, 115
- Mannofucogalactan**, from mushrooms, 156
- Mannofucoxyloglucan**, from mushrooms, 155
- Mannogalactan**, from mushrooms, 152
- Mannogalactofucan**, from mushrooms, 156
- Mannogalactoglucan**, from mushrooms, 155, 156
- Mannoglucan**, from mushrooms, 156

- Mannoglucosylan, from mushrooms, 156
- Mannopyranose, mushroom-related hypoglycemia and, 98
- Mannose
in cultivated mushroom dietary fiber, 78
in sclerotial dietary fiber, 125
- MAPK kinase (MEK)
dendritic cells and, 169
in *Lentinus edodes*, 47
- Marketing licenses, WHO guidelines and, 202
- Mass spectrometry (MS), in antioxidant assays, 92
- Mating factor gene, of *Lentinus edodes*, 40
- Mating-type genes, of *Lentinus edodes*, 38
- Matsutake truffle, 72
as saprophyte, 4
- Maturation, of rind, 116
- Maturation stage, of sclerotial ontogeny, 113, 114
- Mature fruiting body formation, of *Lentinus edodes*, 44–47
- Maturity
of *Lentinus edodes*, 14
in mushroom cultivation, 12
- MBG β -glucan, effects on hematopoietic stem cells, 170
- Medical care, population growth and, 10, 28
- Medical foods, regulation of, 200
- Medications, European Union regulation of, 209
- Medicinal mushroom products, 220. *See also* Mushroom medicinal products
- Medicinal mushrooms
international movement for, 27
Lentinus edodes, 35–36
in mushroom industry, 26
- Medicinal uses/value
of mushroom polysaccharides, 147–198
of mushrooms, xvii, 3, 4, 21–22, 24, 28–29
of *Pleurotus tuber-regium*, 118
of *Polyporus rhinocerus*, 119
of *Wolfiporia cocos*, 120, 121
- Medicines, European Union regulation of, 209
- Medulla
cortex and, 116–117
structure of, 115, 117
- Meiosis, in *Lentinus edodes*, 60–61
- MEK kinase (MEKK), in *Lentinus edodes*, 47
- Melanins, in sclerotial cell walls, 122
- Melanoma cells, 166
- Melon seed ball preparations, *Pleurotus tuber-regium* in, 118
- Memory B cells, dendritic cells and, 168
- Menstruation, *Wolfiporia cocos* in, 120
- Mercury, in cultivated mushrooms. 76
- Metabolic pathways, in *Lentinus edodes*, 48
- Metal oxalates, in sclerotial dietary fiber, 125
- Metals, in cultivated mushrooms, 76. *See also* Heavy metals
- Methanol extracts
in sclerotial antitumor and immunomodulatory studies, 133
in *Wolfiporia cocos* cultivation, 121
- Methionine
in conventional edible mushrooms, 74, 75
in mushroom protein, 88, 89
- Mevinolin, hypocholesterolemic effects of, 96
- mfbC* gene, in *Lentinus edodes*, 46
- Mge1* gene, molecular chaperones and, 59–60
- Mice
antitumor polysaccharide–protein complex studies in, 160, 161
grifolan studies in, 166
lentinan studies in, 165
mushroom-related hypoglycemia studies in, 98, 99
polysaccharide branching configuration studies using, 175
PS-G studies in, 169
PSK studies in, 171
PSPC studies in, 167
PSP studies in, 167
SCG studies in, 164
schizophyllan studies in, 165
sclerotial antitumor and immunomodulatory studies in, 132
studies of chemical improvement of antitumor activity in, 177
- Microarray hybridization, in *Lentinus edodes* genetics, 36, 51, 53–54
- Microfungi, 2
- Microorganisms
in *Agaricus* cultivation, 14
in mushroom cultivation, 13
sclerotial cell walls and, 122
during sclerotial ontogeny, 113
- Mineral binding capacity, of sclerotia, 128–129
- Minerals. *See also* Ash
in conventional edible mushrooms, 75–76, 80
in dietary supplements, 200
European Union regulation of, 209
labeling of, 204–205
in mushrooms, 88
in sclerotial dietary fiber, 125
- Minimum inhibition rates (MIRs), 172
- Ministry of Health (Israel), 214
- Minister of Health, Labor and Welfare (MHLW), in Japan, 212, 213

- Miracle Mushroom Blend, FDA detention of, 207
- Mitochondria, in rind cells, 116
- Mitochondrial DNA (mtDNA) RFLPs, for *Lentinus edodes*, 49. *See also* Deoxyribonucleic acid (DNA)
- Mitogen-activated protein kinase, in *Lentinus edodes* genetics, 52
- Mitosis, of *Lentinus edodes*, 37
- mnp* gene, in *Lentinus edodes* transcriptional regulation, 56
- Moisture
 in conventional edible mushrooms, 73–74
 in nonconventional edible mushrooms, 79, 81
 in sclerotia, 124
 in *Wolfiporia cocos*, 121
- Molecular chaperones, in fungi, 59–60
- Molecular genetics, of *Lentinus edodes*, 48–50
- Molecular markers, for *Lentinus edodes*, 48–49, 49–50
- Molecular mass, of antitumor polysaccharides, 174
- Monilinia*, sclerotia of, 112
- Monilinia fructicola*, lipid bodies in, 123
- Monoclonal antibody (mAb), 164
- Monocytes, 178
 mushroom polysaccharides and, 159
- Monokaryons, of *Lentinus edodes*, 37
- Monokaryotic mycelia, of *Lentinus edodes*, 38
- Monosaccharide residues, of polysaccharides, 148
- Monosodium glutamate (MSG)
 in conventional edible mushrooms, 74–75
 in cultivated mushrooms, 78–79
- Morchella esculenta*, galactomannan from, 166
- Morphogenesis genes, of *Lentinus edodes*, 41
- Morphology
 of sclerotia, 112
 of sclerotia during ontogeny, 112–114
- Mortality patterns, safety and, 215
- Mother spawn
 of *Lentinus edodes*, 14, 15
 in mushroom cultivation, 13–14
- mRNA expression, 164. *See also* Ribonucleic acid (RNA)
- Mucilage matrix, sclerotial ontogeny and, 113
- Multicytokine inducers, polysaccharides and, 148
- Multienzymatic digestion test, in nutritional evaluation, 87
- MultiExperiment Viewer (MeV), in *Lentinus edodes* genetics, 54
- Multihyphal structures. *See also* Hyphae; Hyphal entries
 of filamentous fungi, 111–112
 sclerotial ontogeny and, 113
- Multilocus enzyme electrophoresis, for *Lentinus edodes*, 49
- Mushroom biology, 6–11, 23, 28–29
 applied, 6, 7–11, 28–29
 as a discipline, 7, 8–9
- Mushroom bioremediation, 7, 8, 9, 11, 28
- Mushroom biotechnology, 7–8, 9, 23–25
 dietary supplements and, 24–25
 medicinal value of mushrooms and, 23–24
 nutraceuticals and, 24–25
 nutritional value of mushrooms and, 23–24
- Mushroom cultivation, 1–34. *See also* Cultivation entries
Agaricus, 14
Agaricus brasiliensis, 18–19
Ganoderma lucidum, 19–20
Lentinus edodes, 14–16
 mushroom germplasm in, 20–21
 phases of, 12–13
Pleurotus sajor-caju, 17
 stages of, 13–14
Volvariella, 17–18
- Mushroom industry, 21–23
- Mushroom industry movements, development of, 25–27
- Mushroom medicinal products, regulation of, 200–201. *See also* Medicinal mushroom products
- Mushroom microbiology, 23
- Mushroom nutraceuticals, 3, 9, 10, 11, 24–25, 28–29, 150. *See also* Nutraceuticals
- Mushroom polysaccharides
 antitumor mechanisms of, 153–173, 173–177
 identifying antitumor, 149–153, 154–157, 158–158
 medicinal uses/value of, 147–198, 178–179
 structures and antitumor activities of, 173–177
- Mushroom preparations, safety of, 216
- Mushroom products, submerged culturing of, 219
- Mushrooms, 3–6
 anatomy/structure of, 3–4
 antipollution uses of, 3
 bioactive components of, 89–91
 biological aspects of, xvii
 in biomass waste processing, 28–29
 biosynthesis of phenolic compounds by, 93–94
 as botanical drugs, 218
 chemical aspects of, xvii
 cross breeding of, 56, 57

- cultivation of sclerotia of, 117–121
 defined, 3–4
 as dietary supplements, 3
 domesticated, 2
 ecological classification of, 4, 5
 economic importance of, 72, 73
 edible, 3, 4
 fear of, 2
 fossilized, 2
 health benefits of, 71–109
 hypocholesterolemic effects of, 94–97
 identification of, 4–6
 insects inside, 2
 Israeli regulation of, 214–215
 life cycles of, 149
 lifestyles of, 2–3
 literature on, xvii
 medicinal value of, xvii, 3, 4, 21–22, 28–29
 moisture content of, 23
 nutritional evaluation of, 80–89
 nutritional value of, xvii, 3–4, 28–29, 71–109
 plants versus, 2, 10–11
 poetry about, 2
 poisonous, 2
 poisonous versus edible, 6
 propagation of, 217
 protein quality of, 87–89
 recent interest in, 3
 regulation of, 199–224
 safety of, 215
 sclerotia of, 111–148
 seasonality of, 2–3
 symbiotic with plants, 4
 temperature stress in, 59, 60
 value of, 21–22
 widely cultivated, 72, 73
 world production of, 21–23, 199
- Mushroom science, 7, 8, 9
- Mushroom spawn, in mushroom cultivation, 13.
See also Spawn development phase
- Mushroom species, number of known, 1–2
- Mycelia, 3–4, 179
 in *Agaricus brasiliensis* cultivation, 18
 antitumor polysaccharides from, 152, 159, 160–161
 applied mushroom biology and, 11
 in human diet, 72
 of *Lentinus edodes*, 14, 37, 38
 in *Lentinus edodes* cultivation, 15
 medicinal value of, 149
 mushroom nutraceuticals from, 24–25
 in mushroom vegetative growth phase, 11, 12
 of *Polyporus rhinocerus*, 120
 SAGE profiles of *Lentinus edodes*, 53
 during sclerotial development, 114
 during sclerotial ontogeny, 113
 of *Wolfiporia cocos*, 121
- Mycelial cultures, medicinal effects of, 24
- Mycelial hydrophobins, in *Lentinus edodes*
 genetics, 53
- Mycelial running phase, in mushroom
 cultivation, 12, 13
- Myceteeae, 3
- Mycotoxins, regulation of, 200
- Mycology, 6–7
- “Mycomeat,” 10–11
- Mycophiles, 1
- Mycophobes, 1
- Mycoprotein, 80
- “Mycorestoration,” 11
- Mycorrhiza. *See also* Mycorrhizal mushrooms
 international movement for, 27
 mushrooms as, 4, 5
- Mycorrhizal mushrooms, harvesting of, 21–22
- Myeloid progenitors, PG101 treatment and, 170
- Myotoxins, 92
- Naive B cells, dendritic cells and, 168
- Natural foods, US regulation of, 203
- Natural killer (NK) cells, 166, 178
 in immune response, 161–162
 mushroom polysaccharides and, 150, 163, 167–168
 in sclerotial antitumor and immunomodulatory studies, 133
- Natural personal care products, US regulation of, 203
- Natural Products Association, 208
- Netherlands, food safety systems in, 219–220
- Net protein ratio (NPR), in nutritional evaluation, 87, 88
- Net protein utilization (NPU), 88
- Neurospora crassa*, 37
- Neutral sugars, in cultivated mushroom dietary fiber, 77
- Neutrophils, GLP effects on, 163, 164
- New drug application (NDA), 218
- Newly developed cultivated mushrooms
 chemical composition of, 82
 health and nutritional benefits of, 79–80, 81–87
- New Zealand, 220
 food safety systems in, 219–220
 introducing medicinal-mushroom dietary supplements in, 211–212
- New Zealand Dietary Supplements Regulations (NZDSR), 201

- New Zealand Food Safety Authority (NZFSA), 212
- Niacin, in cultivated mushrooms, 76
- Nicotinamide adenine dinucleotide phosphate (NADPH), in *Lentinus edodes* genetics, 53
- Nigeria, *Pleurotus tuber-regium* consumption in, 118
- Nitric oxide (NO), 151, 153
- Nitric oxide production, in sclerotial antitumor and immunomodulatory studies, 133
- Nonconventional mushrooms, health and nutritional benefits of, 79–80, 81–87
- Nonfat dry milk (NFD), protein quality of, 88
- Nongreen organisms, mushrooms as, 10–11
- Nongreen revolution, mushrooms in, 9–11, 28–29
- Non-insulin-dependent diabetes mellitus (NIDDM), mushroom-related hypoglycemia and, 98
- Nonprotein N, in sclerotia, 124
- Nonstarch polysaccharides (NSPs)
in cultivated mushroom dietary fiber, 77
from mushrooms, 152
- North America
medicinal mushroom uses in, 25
mushroom production in, 22, 23, 73
- Novel foods
in Australia and New Zealand, 212
in Japan, 212–214
- Novel Foods Regulations (Canada), 211
- Nuclear factor kappa B (NF- κ B), 151, 166
dendritic cells and, 169
effects of PG101 and, 165
- Nuclear magnetic resonance (NMR), in
antioxidant assays, 92
- Nucleic acid biosynthesis, in *Lentinus edodes*, 45
- Nucleic acids, in cultivated mushrooms, 78–79.
See also Deoxyribonucleic acid (DNA);
Ribonucleic acid (RNA)
- Nucleotide biosynthesis genes, of *Lentinus edodes*, 41
- Nucleotides, in cultivated mushrooms, 78–79
- Nutraceuticals. *See also* Nutriceuticals
in Canada, 210
regulation of, 200
- Nutriceuticals. *See also* Mushroom nutraceuticals
defined, 200
regulation of, 200–201
sclerotial dietary fiber in, 126
- Nutrients
in conventional edible mushrooms, 73–79,
81–87
direct toxicity of, 216–217
labeling of, 204–205
in mushroom cultivation, 13
during sclerotial development, 114–115
for sclerotial ontogeny, 113–114
- Nutritional evaluation
biological methods for, 80–87
of mushrooms, 80–89
of sclerotia, 123–126
- Nutritional supplements, US regulation of,
203–208
- Nutritional value, of mushrooms, 24, 71–109
- Nutrition Improvement Act of 1992 (Japan), 213
- Nutrition industry, US regulation of, 203
- Office of Nutritional Products, Labeling, and
Dietary Supplements, 205–206
- Office of Special Nutritionals, medical food
regulation by, 200
- Official Journal of the EC*, 209
- Oil-holding capacity (OHC), of sclerotial dietary
fiber, 126, 127
- Oleic acid, in conventional edible mushrooms,
75
- Oligosaccharides
in cultivated mushrooms, 78
in vivo Ca/Mg absorption and, 131, 132
- Omphalia lapidescens*
antitumor polysaccharides from, 154
branching configurations of polysaccharides
from, 175
cultivation of sclerotia of, 117
- Ontogeny, of sclerotia, 112–115
- Oogitake mushrooms, antioxidants in, 89
- Ooi, Vincent E. C., xii, 147
- Organic foods, US regulation of, 203
- Ornithine, in conventional edible mushrooms, 74
- O-sulfonation, in chemical improvement of
antitumor activity, 177
- Ovarian cancer, mushroom polysaccharides
versus, 151
- Ovariectomized (OVX) rats, in vivo Ca/Mg
absorption studies using, 131–132
- Overdoses, US regulations and, 208
- Over-the-counter (OTC) drugs, US regulation of,
205
- Oxalates
in cultivated mushrooms, 79
in sclerotial dietary fiber, 125
- Oxidases, in *Lentinus edodes* genetics, 53
- Oxidation, in biosynthesis of phenolic
compounds, 93
- Oyster mushrooms, 17. *See also* *Pleurotus
ostreatus*
hypcholesterolemic effects of, 96, 97

- p38 MAPK, GLP effects on, 164
- Pachyman
 conformation of, 176
 from mushrooms, 155
- Pachymaran, in chemical improvement of
 antitumor activity, 176
- Pachymic acid, in *Wolfiporia cocos* cultivation,
 121
- Palmitic acid, in conventional edible
 mushrooms, 75
- Parasites, mushrooms as, 4, 5
- Particle bombardment, for *Lentinus edodes*
 transformation, 58
- Pasteurization, in mushroom cultivation, 13
- Pathogens, mushrooms as, 5
- P. atroumborata*, energy content of, 78
- Pattern recognition receptors (PRRs), in immune
 response, 162, 178
- Paxillus involutus*
 polyphosphate granules in, 123
 protein bodies in, 123
 safety of, 216
- Paxillus* syndrome, 216
- Pectic substances, in cultivated mushroom
 dietary fiber, 78
- PEG-mediated transformation, for *Lentinus*
edodes, 56
- Perigold black truffle, as saprophyte, 4
- Peripheral blood lymphocytes (PBLs),
 immunomodulatory responses of, 166–167
- Peristalsis, in colonic fiber fermentation, 129
- Peritoneal exudate cells (PEC)
 GLP effects on, 163
 PSCP effects on, 167
- Peritoneal macrophages (PMs), 166
- Peroxide value, of Japanese mushrooms, 89
- Peroxy radical inhibition, by mushrooms, 91
- PG101 polysaccharide, from *Lentinus lepideus*,
 165, 170
- Phagocytes, 178
- Phagocytic responses, 162
 polysaccharides and, 148
- Phallus impudicus*, biosynthesis of phenolic
 compounds by, 94
- Phanerochaete chrysosporium*, lignin peroxidase
 from, 60
- Pharmaceuticals
 from mushrooms, 10, 11, 28
 regulation of mushroom, 199–200
- Pharmacodynamic agents, safety of, 215
- Pharmacology, of sclerotia, 128–134
- Pharmacopeia monographs, WHO guidelines
 and, 202
- Phaseolus angularis*, protein quality of, 88
- Phaseolus calcaratus*, protein quality of, 88
- Phaseolus vulgaris*, protein quality of, 88
- Phellinus gilvus*, antimetastatic effects of, 171
- Phellinus linteus*
 antitumor polysaccharide–protein complexes
 from, 158
 antitumor polysaccharides from, 154, 157
 polysaccharide–protein complexes from, 160,
 162, 166
 polysaccharides isolated from, 148, 150, 151
 proteoglycan from, 169s
- Phenolic acids, as mushroom antioxidants, 92
- Phenolic antioxidants, in mushrooms, 91–93
- Phenolic compounds
 in cultivated mushrooms, 78
 fungal biosynthesis of, 93–94
 in mushrooms, 88–89, 90–91
- Phenolic pigments, in sclerotial cell walls, 122
- Phenotypic variation, in mushroom cultivation,
 20
- Phenylacetic acid, biosynthesis of, 93
- Phenylalanine
 biosynthesis of, 93
 in conventional edible mushrooms, 75
- Pholiota adiposa*, 86
 chemical composition of, 82
 classification of, 80
- Pholiota nameko*, 87
 chemical composition of, 82
 classification of, 80
 world production of, 73
- Phosphatidyl biosynthesis, mushroom-related
 hypocholesterolemia and, 94
- Phosphatidylcholine (PC), mushroom-related
 hypocholesterolemia and, 94
- Phosphatidylethanolamine (PE),
 mushroom-related hypocholesterolemia
 and, 94
- Phosphatidylinositol 1-kinase (PI3K), GLP
 effects on, 164
- Phosphorus
 in cultivated mushrooms, 76
 in mushrooms, 23
 in sclerotial dietary fiber, 125
- Photosynthesis, as lacking in mushrooms, 10, 28
- pH values, of sclerotial dietary fiber, 126
- Physicochemical properties, of sclerotia,
 126–128
- Physiological processes, in *Lentinus edodes*,
 47–48, 61
- Physiology, of sclerotia during ontogeny,
 114–115
- Phytic acids, in cultivated mushrooms, 79
- Phytochemicals, regulation of, 200

- PicoTitle Plate, in *Lentinus edodes* sequencing by synthesis, 55
- Pigmentation, of cortex, 116. *See also* Color entries
- Pigments, in sclerotial cell walls, 122
- Pinto beans, protein quality of, 88
- Pinus densiflora*, in *Wolfiporia cocos* cultivation, 121
- Planting spawn
of *Lentinus edodes*, 14, 15–16
in mushroom cultivation, 13–14
- Plants
mushrooms versus, 2, 10–11
symbiotic with mushrooms, 4
- Plasma, mushroom effects on, 97
- Plasma membrane, in *Lentinus edodes* genetics, 51–52
- Plasmid DNA, in *Lentinus edodes* transformation, 57–58
- Plastic bags, in *Ganoderma lucidum* cultivation, 20
- Platelets, mushroom effects on, 97
- pLC1-hph plasmid, in *Lentinus edodes* transformation, 57–58
- Pleurotaceae, classification of, 80
- Pleurotus*, 83–84
biology and genetics of, 17
chemical compositions of, 81
health and nutritional benefits of, 79
hypocholesterolemic effects of, 96
protein and amino acid content of, 74
protein quality of, 88
world production of, 72, 73
- Pleurotus abalones*, 83
chemical composition of, 81
classification of, 80
- Pleurotus citrinopileatus*, 83
antitumor polysaccharide–protein complexes from, 158
antitumor polysaccharides from, 156
chemical composition of, 81
classification of, 80
dietary fiber in, 77
protein and amino acid content of, 75
- Pleurotus cornucopiae*, 83
antitumor polysaccharides from, 156
chemical composition of, 81
classification of, 80
hypocholesterolemic effects of, 96
- Pleurotus cystidiosus*
antioxidants in, 90
carbohydrate content of, 78
dietary fiber in, 77
moisture content of, 73
- Pleurotus djamor*, 83
chemical composition of, 81
classification of, 80
- Pleurotus eryngii*, 83
antitumor polysaccharides from, 155, 156
chemical composition of, 81
classification of, 80
hypocholesterolemic effects of, 96
world production of, 72, 73
- Pleurotus eryngii* var *ferulae*, 83. *See also* *Pleurotus ferulae*
ash and mineral content of, 76
chemical composition of, 81
classification of, 80
moisture content of, 73
protein and amino acid content of, 74, 75
- Pleurotus eryngii* var *nebrodensis*, 84. *See also* *Pleurotus nebrodensis*
chemical composition of, 81
classification of, 80
- Pleurotus ferulae*, chemical composition of, 81, 82. *See also* *Pleurotus eryngii* var *ferulae*
- Pleurotus florida*
antitumor polysaccharides from, 155
immunomodulating polysaccharide from, 166
polysaccharides isolated from, 153
- Pleurotus nebrodensis*, 84. *See also* *Pleurotus eryngii* var *nebrodensis*
chemical composition of, 81
classification of, 80
- Pleurotus ostreatoroseus*, antitumor polysaccharides from, 155
- Pleurotus ostreatus*, 56, 57, 58, 59, 84
antioxidants in, 90, 92
antitumor glucans from, 157–159
antitumor polysaccharide–protein complexes from, 158
antitumor polysaccharides from, 157
ash and mineral content of, 76
carbohydrate content of, 78
chemical composition of, 81
classification of, 80
energy content of, 78
fat content of, 75
hypocholesterolemic effects of, 96
moisture content of, 73
polysaccharides isolated from, 152
protein and amino acid content of, 74, 75
protein quality of, 88
vitamin content of, 76–77
- Pleurotus pulmonarius*, 84
antitumor polysaccharides from, 155, 156
chemical composition of, 81

- classification of, 80
 moisture content of, 73
- Pleurotus sajor-caju*
 antitumor polysaccharide-protein complexes from, 158
 antitumor polysaccharides from, 157
 cultivation of, 17
 dietary fiber in, 77
 lignocellulolytic enzymes of, 10
 polysaccharides isolated from, 152
 temperature stress in, 59
- Pleurotus sapidus*, 84
 chemical composition of, 81
 classification of, 80
 hypocholesterolemic effects of, 96
- Pleurotus tuber-regium*, 121
 antioxidants in, 90, 92
 antitumor effects of, 132-133
 antitumor polysaccharides from, 155
 biopharmacological value of sclerotia from, 128-134
 chemical improvement of antitumor polysaccharides from, 177
 cultivation of sclerotia of, 117
 dietary fiber in, 125, 126-128
 fermentation of dietary fiber from, 130
 in vivo Ca/Mg absorption and, 131
Polyporus rhinocerus versus, 119
 polysaccharides isolated from, 152-153
 preparation of dietary fiber from, 126
 proximate composition of, 123-124
 sclerotia of, 118-119
- Pluteaceae, classification of, 80
- Poisonous mushrooms, distinguishing from edible, 6
- Poland, mushroom production in, 21
- Pollution
 applied mushroom biology and, 9, 11
 mushrooms versus, 3
 population growth and, 10, 28
- Polyethylene glycol (PEG), 56
- Polymerase chain reaction (RAP-PCR), in
Lentinus edodes genetics, 36, 50, 51-52
- Polymeric chain reactions (PCRs), in generating
Lentinus edodes molecular markers, 48,
 49-50, 61
- Polymers, polysaccharides as, 148
- Polyphosphates, in sclerotial cytoplasmic reserves, 122, 123
- Polyporaceae, 119
 classification of, 80
- Polyporus confluens*
 antitumor polysaccharide-protein complexes from, 159
 antitumor polysaccharides from, 155, 156, 157
 hypolipidemic effects of, 95
- Polyporus mylittae*
 sclerotial germination of, 114
 sclerotia of, 112
- Polyporus rhinocerus*, 121
 antitumor effects of, 132-133
 biopharmacological value of sclerotia from, 128-134
 classification of, 119
 cultivation of sclerotia of, 117
 dietary fiber in, 125, 126-128
 fermentation of dietary fiber from, 130
 in vivo Ca/Mg absorption and, 131
 preparation of dietary fiber from, 126
 proximate composition of, 123
 sclerotia of, 119-120
- Polyporus tumulosus*, biosynthesis of phenolic compounds by, 93
- Polysaccharide extracts, of mushrooms, 89-90
- Polysaccharide from *Ganoderma lucidum* (PS-G), 163-164. *See also* *Ganoderma lucidum* polysaccharide (GLP)
 dendritic cells and, 169
- Polysaccharide-hydrolytic enzymes, in sclerotial cell walls, 122
- Polysaccharide medicines, from mushrooms, 25
- Polysaccharide-protein complex (PSPC). *See also* PSP polysaccharide-protein complex
 mushrooms and, 24, 25, 160, 167
 structure and antitumor activity of, 173-174
- Polysaccharide-protein complexes, 148,
 149-150, 152, 153, 178, 179
 from mushrooms, 158-159
- Polysaccharides, 178-179. *See also* Mushroom polysaccharides
 in cultivated mushroom dietary fiber, 77
 dietary fiber and, 124
 in vivo Ca/Mg absorption and, 131, 132
Lentinus edodes degradation of, 36-37
 mushroom-related hypoglycemia and, 98
 in mushrooms, 25
 in sclerotial dietary fiber, 125
 structural features of, 148
 of *Wolfiporia cocos*, 120
- Polysaccharopeptide (PSP), from mushrooms, 150. *See also* PSP polysaccharide-protein complex
- Polynaturated fatty acids, in conventional edible mushrooms, 75, 80
- Polyuronides, in sclerotial dietary fiber, 125
- Population growth, applied mushroom biology and, 9-10, 28

- Poria cocos*, 120. *See also* *Wolfiporia cocos*
 antitumor polysaccharides from, 155, 159, 160–161
 branching configurations of polysaccharides from, 174–175
 in chemical improvement of antitumor activity, 177
 conformation of polysaccharides from, 176
 Pork sausage, *Pleurotus tuber-regium* in, 118
Porodisculus pendulus, antitumor polysaccharides from, 155
 Postharvest studies, of *Lentinus edodes*, 59, 61
 Potassium
 in cultivated mushrooms, 76
 in nonconventional edible mushrooms, 79
 Potato dextrose agar (PDA), in *Lentinus edodes* cultivation, 15
 Pregnancy, *Wolfiporia cocos* in, 120
 Preparation, of sclerotial dietary fiber, 126
PriA gene
 in *Lentinus edodes* primordium formation, 38
 in *Lentinus edodes* transcriptional regulation, 55, 56
Lentinus edodes transformation and, 58–59
PriA gene promoter, in *Lentinus edodes* transformation, 57, 59
PriA gene terminator, in *Lentinus edodes* transformation, 57, 59
PriB gene, in *Lentinus edodes* transcriptional regulation, 55, 56
 PRIB protein, in *Lentinus edodes* primordium formation, 38–43
 PRIB regulator, in *Lentinus edodes*, 46
 Primordium, SAGE profiles of *Lentinus edodes*, 53
 Primordium development genes, of *Lentinus edodes*, 43, 44–47
 Primordium formation, in *Lentinus edodes*, 38–44
 Procatechoic acid, in mushrooms, 91, 92
 Process analysis, of *Lentinus edodes*, 59–61
 Prohibition of Exaggerated and Misleading Claims law, in Japan, 214
 Promoter analysis, in *Lentinus edodes* transcriptional regulation, 55–56
 Propagation, of mushrooms, 217
 Propionate, colonic fermentation and, 130
 Prosenchymatous tissue, in medulla, 117
 Prostatic cancer
 antimetastatic effects on, 171
 mushroom polysaccharides versus, 150, 157
 Protein. *See also* polysaccharide–protein complexes; Proteins
 in conventional edible mushrooms, 74–75
 from mushrooms, 10–11, 23, 72, 80
 in nonconventional edible mushrooms, 79, 81
 in sclerotial cytoplasmic reserves, 122, 123
 Protein Advisory Group of United Nations System, 79
 Protein bodies, in sclerotial cytoplasmic reserves, 123
 Protein chelators, in vitro sclerotial binding of minerals and, 128–129
 Protein degradation genes, of *Lentinus edodes*, 42
 Protein digestibility, in nutritional evaluation, 87
 Protein-digestibility-corrected amino acid score (PDCAAS), in nutritional evaluation, 87
 Protein efficiency ratio (PER), in nutritional evaluation, 87, 88
 Protein enrichment, via mushroom cultivation, 21, 22
 Protein kinase C (PKC), 164, 166
 Protein phosphates, in *Lentinus edodes*, 45
 Protein quality, of mushrooms, 87–89
 Proteins
Lentinus edodes degradation of, 36
 in *Lentinus edodes* genetics, 53
 as molecular chaperones, 59–60
 in mushrooms, 25
 polysaccharides and, 148
 Protein tyrosine kinase (PTK), 166
 Proteoglycans
 in immune response, 162
 immunomodulatory effects of, 169
 from mushrooms, 158
 Protocatechuic acid
 biosynthesis of, 93
 as mushroom antioxidant, 92
 Proximate composition, of sclerotia, 123–124
 PSK polysaccharide–protein complex. *See also* Krestin
 in angiogenesis, 172
 antimetastatic effects of, 171
 conformation of, 175
 immunomodulatory effects of, 166–167, 169–170
 isolation of, 148, 150
 molecular masses of fractions of, 174
 from mushrooms, 158, 159–160, 161–162
 structure and antitumor activity of, 173–174
 PSP polysaccharide–protein complex. *See also* polysaccharide–protein complex (PSPC); Polysaccharopeptide (PSP)
 isolation of, 148, 150
 from mushrooms, 158, 159–160, 167
 structure and antitumor activity of, 173–174
 Pyruvate decarboxylase, in *Lentinus edodes*, 48

- Qualified FOSHU, in Japan, 213
- Qualified health claims, 206
- Quality control, 220
in European Union, 209
of mushroom dietary supplements, 201
- Radiation treatment, mushrooms and, 25
- Rain forests, mushrooms in, 2
- Random-amplified polymorphic DNA (RAPD),
in generating *Lentinus edodes* molecular
markers, 48, 49, 61
- Ras* gene promoter, in *Lentinus edodes*
transformation, 57, 59
- Rats
in vivo Ca/Mg absorption studies using,
131–132
mushroom protein intake by, 88, 89
mushroom-related hypocholesterolemia
studies in, 94
mushroom-related hypoglycemia studies in,
98, 99
- Reactive nitrogen intermediates (RNIs), 160
PSPC effects on, 167
- Recombinant DNA (rDNA), in mushroom
cultivation, 20. *See also* Deoxyribonucleic
acid (DNA)
- RecQ-type DNA helicase, in *Lentinus edodes*, 46
- Redness, of sclerotial dietary fiber, 126
- Reduction of Disease Risk FOSHU, in Japan,
213–214
- Reference works, in mushroom identification, 6
- Regulation
of mushrooms, 199–224
standardization problems with, 201
- Regulatory mechanisms, polysaccharides in, 148
- Reishi mushroom, 207
- Representational difference analysis
(cDNA-RDA), in *Lentinus edodes* genetics,
36. *See also* cDNA representational
difference analysis (cDNA-RDA)
- Reproductive growth phase, in mushroom
cultivation, 11–12
- Reproductive organs, of filamentous fungi,
111–112
- Restriction enzyme–linearized plasmid DNA, in
Lentinus edodes transformation, 57–58
- Restriction enzyme–mediated integration
(REMI), for *Lentinus edodes*
transformation, 57–58
- Restriction enzymes, in *Lentinus edodes*
transformation, 57–58
- Restriction fragment length polymorphisms
(RFLPs), in generating *Lentinus edodes*
molecular markers, 48, 49
- Rhamnoglucogalactan, from mushrooms, 156
- Rhamnose
in cultivated mushroom dietary fiber, 78
in sclerotial dietary fiber, 125
- Rhizomorphs, of filamentous fungi, 111, 112
- Riboflavin, in cultivated mushrooms, 76
- Riboglucan, from mushrooms, 155
- Ribonucleic acid (RNA), in cultivated
mushrooms, 79. *See also* mRNA
expression; RNA synthesis
- Ribonucleic acid fingerprinting, of *Lentinus
edodes*, 36
- Ribonucleic acid–reduced biomass, from fungal
hyphae, 80
- Ribonucleotide reductase (RNR)
in *Lentinus edodes*, 45
in *Lentinus edodes* meiosis, 60–61
- Rice straw, in *Volvariella* cultivation, 17–18
- Rigidoporus ulmarius*, antiangiogenesis and, 173
- Rind
cortex and, 116
of *Polyporus rhinocerus*, 119
in sclerotial ontogeny, 113
structure of, 115–116
of *Wolfiporia cocos*, 120
- RNA synthesis, in *Lentinus edodes*, 45. *See also*
Ribonucleic acid (RNA)
- Rolled oats, protein quality of, 88
- Saccharomyces cerevisiae*, 46, 57, 56
- Safety, 220. *See also* Food safety systems
defined, 215–216
of dietary supplement types, 215–218
of functional foods, 208
via submerged culturing, 219
WHO guidelines and, 202
- Safety warnings, for US dietary supplements,
205
- SAGE 2000 Software, in *Lentinus edodes*
genetics, 52
- Salmonella typhimurium*, in antioxidant assays,
92
- Sammin Mycological Institute, 79, 81, 82
- Sanger sequencing technology, in *Lentinus
edodes* sequencing by synthesis, 55
- Saprophytes, mushrooms as, 4, 5
- Sarcodon aspratus*
antitumor polysaccharides from, 157 –
fucogalactan from, 166
- Sarcoma, 175
antimetastatic effects on, 171
chemical improvement of antitumor activity
versus, 177

- Sarcoma, (*Continued*)
 mushroom polysaccharide–protein complexes versus, 160
 mushroom polysaccharides versus, 150–151
- Sawdust, in *Lentinus edodes* cultivation, 16
- SCG (*Sparassis crispa* β -glucan), 151
 immunomodulatory effects of, 164, 170–171
- Schizophyllan
 antitumor effects of, 165
 branching configuration of, 175
 in chemical improvement of antitumor activity, 176
 conformation of, 175
 isolation of, 148, 150
 from mushrooms, 155, 161, 165
 regulation of, 200
- Schizophyllan-OH, conformation of, 176
- Schizophyllum commune*, 38
 antitumor polysaccharides from, 155
 carbohydrate content of, 78
 fat content of, 75
 medicines from, 25
 moisture content of, 74
 polysaccharides isolated from, 148, 150
 protein and amino acid content of, 74
 protein quality of, 88
 regulation of polysaccharides from, 199–200
- Schizosaccharomyces pombe*, 43
- Science, in mushroom cultivation, 20–21
- Scleroglucan, from mushrooms, 155
- Sclerotia, xvii, 111–146, 178
 antitumor polysaccharides from, 159
 biochemical characteristics of, 121–123
 biopharmacological values of, 128–134
 cell walls of, 121–122
 cultivation of, 117–121
 cytoplasmic reserves of, 122–123
 dietary fiber in, 124–126
 extracellular matrix of, 122
 in human diet, 72
 lipid bodies in, 123
 medicinal value of, 149
 morphology and size of, 112
 nutritional evaluation of, 123–126
 ontogeny of, 112–115
 physicochemical properties of, 126–128
 polyphosphate granules in, 123
 protein bodies in, 123
 structure of, 115–117
 world production of, 117
- Sclerotinia*
 cortex of, 117
 sclerotial germination of, 114
 sclerotia of, 112
- Sclerotiniaceae, sclerotia of, 112
- Sclerotinia libertiana*, antitumor polysaccharides from, 155
- Sclerotinia minor*
 cortex of, 115
 glycogen reserves of, 122
 rind of, 116
 sclerotial germination of, 114
- Sclerotinia sclerotiorum*, rind of, 116
- Sclerotinia trifoliorum*, rind of, 116
- Sclerotinium sclerotiorum*, sclerotial germination of, 114
- Sclerotium rolfsii*
 ontogeny of, 113
 sclerotia of, 112
- Sclerotium sclerotia*, antitumor polysaccharides from, 155
- Seasonality, of mushrooms, 2–3
- Secretion phase, in mushroom cultivation, 12, 13
- Selection phase, in mushroom cultivation, 12–13
- Selective breeding, in mushroom cultivation, 20
- Selenium, in cultivated mushrooms, 76
- Selenium enrichment, of mushrooms, 24
- Septa, of rind, 115
- Sequence characterized amplified region (SCAR) markers, for *Lentinus edodes*, 48, 49, 50
- Sequence tags, in *Lentinus edodes* genetics, 52, 53
- Sequencing-by-synthesis approach (454 Life Science), in *Lentinus edodes* genetics, 36, 51, 54–55, 60
- Serial analysis of gene expression (SAGE), in *Lentinus edodes* genetics, 36, 50, 51, 52–53, 61
- Serine-rich proteins, in *Lentinus edodes* genetics, 53
- Serious adverse effects, under US regulations, 208
- Serum, mushroom effects on, 97
- Serum total cholesterol (TC), mushrooms reducing, 97
- S-GAP-P polysaccharide, in chemical improvement of antitumor activity, 176
- Shiitake mushroom, xvii, 14, 35–69, 207. *See also Lentinus edodes*
 hypocholesterolemic effects of, 94
 popularity of, 35
 safety of, 215
- Shikimic acid pathway, in phenolic compound biosynthesis, 93
- Short-chain fatty acids (SCFAs), colonic fermentation and, 129–130

- Short-log cultivation, of *Ganoderma lucidum*, 19–20
- Signal transduction, in *Lentinus edodes*, 47, 61
- Signal transduction genes
in *Lentinus edodes*, 44–45, 54
in *Lentinus edodes* primordium formation, 38, 39–40
- Single-helix conformation, 175, 176
- Size, of sclerotia, 112
- Sodium
in cultivated mushrooms, 76
in nonconventional edible mushrooms, 79
- Solid-state fermentation, in mushroom cultivation, 10–11
- Soluble dietary fiber (SDF)
in cultivated mushrooms, 77, 81
of sclerotia, 124, 125
- Soluble sugars, in cultivated mushrooms, 78
- Soup, *Pleurotus tuber-regium* in, 118
- South Australian Working Party on Natural and Nutrition Supplements, 211
- South East Asia, *Volvariella* cultivation in, 17–18
- Soybean waste, applied mushroom biology and, 11
- Sparassis crispa*, 164
antitumor polysaccharides from, 155
branched β -glucan from, 170–171
polysaccharides isolated from, 148, 150, 151
- Spawn development phase, in mushroom cultivation, 12, 13
- Spawn inoculation, of *Wolfiporia cocos*, 121
- Spawn running
in *Agaricus* cultivation, 14
of *Lentinus edodes*, 14
in mushroom cultivation, 13
- Spawn substrates
in *Lentinus edodes* cultivation, 15–16
in *Pleurotus* cultivation, 17
- Specialists, in mushroom identification, 6
- Specialization, in biology, 7
- Spleen cells (splenocytes), mushroom polysaccharide effects on, 163–167
- Spore formation genes, of *Lentinus edodes*, 41
- Spore germination, in *Lentinus edodes* cultivation, 15
- Spore print, in mushroom identification, 5
- Spores, in mushroom identification, 5
- Sporobolomyces roseus*, biosynthesis of phenolic compounds by, 93
- Ssb* gene, molecular chaperones and, 59–60
- Stabilization, of sclerotial dietary fiber, 126
- Stalk, in mushroom identification, 5
- Standardization
in Australia and New Zealand, 211–212
of European dietary supplements, 209
of mushroom dietary supplements, 201
- Standardized FOSHU, in Japan, 213
- Starch, *Lentinus edodes* degradation of, 36–37
- Starch utilization genes, of *Lentinus edodes*, 40
- Sterilization, in mushroom cultivation, 13
- Sterols, as mushroom antioxidants, 92
- Stil* gene, molecular chaperones and, 59–60
- Stipe elongation, in *Lentinus edodes*, 44
- Stock culture
in mushroom cultivation, 13
preparation of, 13–14
- Strains, of *Lentinus edodes*, 50
- Strands
of filamentous fungi, 111
in sclerotial ontogeny, 113
- Straw mushroom, 17–18. *See also* *Volvariella*
hypocholesterolemic effects of, 97
- Streptomyces hygroscopicus*, 57
- Streptozotocin (STZ), mushroom-related hypoglycemia and, 98, 99
- Stress response genes, of *Lentinus edodes*, 42
- Stress responses, of *Lentinus edodes*, 59–60, 61
- Stromata, of filamentous fungi, 111
- Strophariaceae, classification of, 80
Stropharia rugoso-annulata, 87
chemical composition of, 82
classification of, 80
- Structural proteins, in *Lentinus edodes*, 48
- Structure, of sclerotia, 115–117
- Structure–function (SF) claims, US regulation of, 205–208
- Submerged culturing, safety via, 219
- Substrate, in sclerotial ontogeny, 113–114. *See also* Cultivation substrate
- Substrate preparation phase
in *Agaricus brasiliensis* cultivation, 18–19
in *Ganoderma lucidum* cultivation, 19–20
in *Lentinus edodes* cultivation, 15–16
in mushroom cultivation, 12, 13, 14
in *Pleurotus* cultivation, 17
- Substrate-specific factors, in colonic fiber fermentation, 129
- Substrate-utilizing genes, of *Lentinus edodes*, 36–37
- Sugar residues, in sclerotial dietary fiber, 125
- Sugars. *See also* Carbohydrates
in conventional edible mushrooms, 75
in cultivated mushroom dietary fiber, 77–78
in mushrooms, 25
- Suillus*, peroxide value of, 89
- Sulfation, in chemical improvement of antitumor activity, 176, 177

- Sulfonation, in chemical improvement of antitumor activity, 177
- Sulfur-containing amino acids, in mushroom protein, 88, 89
- Superoxide free radicals, mushroom scavenging of, 89–90
- Supplement facts box, in labeling, 204–205
- Suppression subtractive hybridization, of *Lentinus edodes*, 51
- Sweet components, in conventional edible mushrooms, 75
- Symphytum officinale*, safety of, 216
- Synnemata, of filamentous fungi, 111, 112
- Tags, in *Lentinus edodes* genetics, 52, 53. *See also* Expressed sequence tags (ESTs)
- Taiwan, *Wolfiporia cocos* consumption in, 120–121
- Tannins, in mushrooms, 88
- TATA box, in *Lentinus edodes* transcriptional regulation, 55–56
- TCA (tricarboxylic acid; citrate) cycle, in *Lentinus edodes*, 48. *See also* Tricarboxylic acid (TCA)
- T cells
 - D-fraction and, 167–168
 - effects of lentinan on, 165
 - mushroom polysaccharides and, 150
 - PSK response of, 166–167
- TCPI* gene, molecular chaperones and, 59–60
- Technological innovation, in mushroom industry, 22
- Temperature
 - in *Agaricus brasiliensis* cultivation, 18
 - in *Agaricus* cultivation, 14
 - in *Lentinus edodes* cultivation, 15
 - in *Pleurotus* cultivation, 17
 - in *Volvariella* cultivation, 17–18
- Temperature stress, in mushrooms, 59, 60
- Terfezia armenari*, 2
- Terfezia claveryi*, protein quality of, 88
- Terminal cells, of rind, 115–116
- Terminal development, of sclerotia, 113
- Termitomyces eurhinus*, antitumor polysaccharides from, 155
- Termitomyces robustus*
 - energy content of, 78
 - protein quality of, 88
- Texture, of sclerotial dietary fiber, 126
- The Institute for Genome Research (TIGR), in *Lentinus edodes* genetics, 54
- Therapeutic adjuvants, mushroom polysaccharides as, 147–148
- Therapeutic agents, from mushrooms, 150
- Therapeutic pharmacodynamic activity, safety of, 215
- Thickening, of sclerotial dietary fiber, 126
- Thin-layer chromatography (TLC), in antioxidant assays, 92
- Threonine
 - in conventional edible mushrooms, 74, 75
 - in mushroom protein, 89
- Tiger milk mushroom, 118
- tlg1* gene, in *Lentinus edodes*, 59
- TLR pathway, in immune response, 162
- Toads, mushrooms and, 2
- Toadstools, 2
- α -Tocopherol, in mushroom antioxidant assays, 90, 92
- Total color difference, of sclerotial dietary fiber, 126
- Total dietary fiber (TDF)
 - in cultivated mushrooms, 77–78
 - in nonconventional edible mushrooms, 79, 81
 - in sclerotia, 125
- Total productivity, of biomass materials, 28
- Toxicity
 - of mushrooms, 6
 - of nutrients, 216–217
- Toxic substances, in mushroom cultivation, 13
- Traditional mushroom products, safety of, 216
- Trametes*, hypolipidemic effects of, 95
- Trametes gibbosa*, antitumor polysaccharides from, 155
- Trametes versicolor*, regulation of polysaccharides from, 199–200. *See also* *Coriolus (Trametes) versicolor*
- Transcriptional factor binding sites (TFBSs), in *Lentinus edodes* transcriptional regulation, 55
- Transcriptional factors (TFs), in *Lentinus edodes* transcriptional regulation, 55
- Transcriptional regulation, of *Lentinus edodes*, 55–56
- Transcription regulation genes, in *Lentinus edodes* primordium formation, 38, 39–40
- Transformation, of *Lentinus edodes*, 56–59
- Transformation methods, for *Lentinus edodes*, 56–58
- Transgenic breeding, transformation in, 56, 57
- Translocation, of sclerotia during ontogeny, 114–115
- Transmission electron microscopy (TEM), in sclerotial cytoplasm studies, 122
- Transport genes, of *Lentinus edodes*, 38, 41
- Trehalose
 - in cultivated mushrooms, 78
 - during sclerotial development, 114

- Tremella*, Chinese production of, 72, 73
- Tremella aurantia*
 dietary fiber in, 125
 hypolipidemic effects of, 95
 mushroom-related hypoglycemia and, 98–99
- Tremella cinnabarina*, world production of, 73
- Tremella fuciformis*
 antitumor polysaccharide–protein complexes from, 159
 antitumor polysaccharides from, 156, 157
 dietary fiber in, 77, 125
 hypocholesterolemic effects of, 97
 hypolipidemic effects of, 95
 mushroom-related hypoglycemia and, 98–99
- Tremella mesenterica*, antitumor polysaccharides from, 157
- Triangular model, for mushroom classification, 5
- Tricarboxylic acid (TCA), *Lentinus edodes* and, 44. *See also* TCA (tricarboxylic acid; citrate) cycle
- Tricholoma*, 173
- Tricholoma giganteum*
 antioxidants in, 90
 antitumor polysaccharide–protein complexes from, 159
 antitumor polysaccharides from, 155, 157
 carbohydrate content of, 78
 dietary fiber in, 77
 fat content of, 75
 protein and amino acid content of, 74
 world production of, 73
- Tricholoma lobayense*
 antitumor polysaccharide–protein complexes from, 159
 medicines from, 25
 polysaccharide–protein complexes from, 160, 167
- Tricholoma matsutake*, 72
 antitumor polysaccharide–protein complexes from, 159
 ecological classification of, 5
 as saprophyte, 4
- Tricholoma mongolicum*, antitumor polysaccharide–protein complexes from, 159
- Tricholoma portentosum*
 dietary fiber in, 77
 protein and amino acid content of, 74, 75
 protein quality of, 88
- Tricholomataceae, 35
 antioxidants in, 90
 classification of, 80
- Tricholoma terreum*
 carbohydrate content of, 78
 dietary fiber in, 77
 fat content of, 75
 protein and amino acid content of, 74, 75
 protein quality of, 88
- Triggers
 in *Lentinus edodes* primordium formation, 38
 in mushroom cultivation, 12
- Triglycerides, mushrooms as lowering, 96–97
- Triple-helix conformation, 175–176
- Triterpenes
 in mushrooms, 25
 in sclerotial antitumor and immunomodulatory studies, 133
- True protein digestibility (TPD), of mushrooms, 88
- Truffles
 desert, 2
 matsutake, 4, 5
 Pengold black, 4
- Tryptophan
 biosynthesis of, 93
 in conventional edible mushrooms, 74, 75
- Tuber melanosporum*, 72
 ecological classification of, 5
 as saprophyte, 4
- Tumor necrosis factor alpha (TNF- α), 151, 160, 163, 164, 166, 167, 178
 effects of lentinan on, 165
- Tumor xenografts, in sclerotial antitumor and immunomodulatory studies, 133–134
- Tuna fish, protein quality of, 88
- Tylophilus felleus*, antitumor polysaccharides from, 155
- Type 2 diabetes, 207
- Typhula*, sclerotia of, 112
- Typhula incarnata*
 cortex of, 117
 medulla of, 117
 protein bodies in, 123
 rind of, 116
- Typing, of *Lentinus edodes*, 50
- Tyrosine
 biosynthesis of, 93
 in conventional edible mushrooms, 75
- Ubiquitins, of *Lentinus edodes*, 43–44
- Umami flavor, of edible mushrooms, 74–75, 78–79
- Umbilical cord blood (CB) cells, 170
- UMP-CMP kinase, in *Lentinus edodes*, 45
- United Kingdom
 food safety systems in, 219–220
 mushroom nutraceutical regulation in, 201
 regulation of dietary supplements in, 210

- United States, 220. *See also* American entries;
Federal entries; Food and Drug
Administration (FDA)
drug regulation in, 218
food safety in, 215
introducing medicinal-mushroom dietary
supplements in, 203–208
medicinal mushroom use in, 25
mushroom nutraceutical regulation in, 200,
201
- Unsaturated fatty acids, in conventional edible
mushrooms, 75, 80
- Uronic acids
in cultivated mushroom dietary fiber, 77, 78
in sclerotial dietary fiber, 125
- Vacuolation, of cortex, 116
- Vacuoles, in rind cells, 116
- Valine
in conventional edible mushrooms, 74, 75
in mushroom protein, 89
- Variability, of polysaccharides, 148
- Vascular endothelial growth factor (VEGF), in
angiogenesis, 172
- Vegetables, mushrooms as, 72
- Vegetative growth phase, in mushroom
cultivation, 11, 12
- Verticillium dahliae*
lipid bodies in, 123
sclerotia of, 112
- Vietnam, mushroom production in, 21
- Vitamin B₁, in cultivated mushrooms, 77
- Vitamin B₂, in cultivated mushrooms, 76
- Vitamin B₁₂, in cultivated mushrooms, 77
- Vitamin B₁₂ deficiency, 217
- Vitamin C
in cultivated mushrooms, 77
mushroom polysaccharides and, 150
- Vitamin D₂, in cultivated mushrooms, 77
- Vitamins
in conventional edible mushrooms, 76–77
in dietary supplements, 200
European Union regulation of, 209
labeling of, 204–205
in mushrooms, 23, 80
in nutrition, 23
- Vitapurity, FDA detention of, 207
- Volvariella*
cultivation of, 17–18
industrial-scale cultivation of, 18
world production of, 72, 73
- Volvariella bombycina*
dietary fiber in, 77
fat content of, 75
protein and amino acid content of, 75
- Volvariella volvacea*, 58
anatomy of, 3
antioxidants in, 90, 91
antitumor polysaccharides from, 155
carbohydrate content of, 78
classification of, 80
hypocholesterolemic effects of, 97
hypolipidemic effects of, 95
lignocellulolytic enzymes of, 10
medicinal effects of, 24
protein and amino acid content of, 74
world production of, 73
- Wasser, Solomon P., xxi, 27, 199
- Wasson, R. Gordon, 1
- Wastes, applied mushroom biology and, 9,
10–11, 28
- Water
in nutrition, 23
during sclerotial development, 114
- Water-binding capacity (WBC), of sclerotial
dietary fiber, 126, 127
- White jelly-leaf mushroom, hypocholesterolemic
effects of, 97
- Whiteness, of sclerotial dietary fiber, 126
- White rot fungus
Lentinus edodes as, 60
Polyporus rhinocerus as, 119
- WHO Food Standards Programme, 202–203.
See also World Health Organization (WHO)
- WHO Nutrient Risk Project, 203
- Wild edible fungi, Israeli regulation of, 214–215
- Wild Edible Fungi: A Global Overview of Their
Use and Importance to People* (FAO),
214–215
- Wild edible mushrooms, health and nutritional
benefits of, 79–80, 81–87
- Wild mushrooms
edible, 72, 73
international movement for, 27
in mushroom industry, 26
- Wolfiporia cocos*. *See also* *Poria cocos*
antitumor effects of, 133
biopharmacological value of sclerotia from,
128–134
cultivation of sclerotia of, 117
dietary fiber in, 125–126, 126–128
fermentation of dietary fiber from, 130–131
hypolipidemic effects of, 95
in vivo Ca/Mg absorption and, 131–132
preparation of dietary fiber from, 126
proximate composition of, 123, 124
sclerotia of, 120–121

- Wong, Ka-Hing, xxi, 111
- Wood
- in biomass waste, 10
 - in *Ganoderma lucidum* cultivation, 19–20
 - in *Lentinus edodes* cultivation, 15, 16
 - in *Wolfiporia cocos* cultivation, 121
- Wood rot fungus
- Lentinus edodes* as, 15
 - Pleurotus tuber-regium* as, 118
- Working Party on Natural and Nutrition Supplements, 211
- World Health Organization (WHO). *See also* WHO entries
- on introducing medicinal-mushroom dietary supplements, 202, 220
 - on mushroom protein and amino acid content, 74
- World mushroom production, 21–23
- World population growth, applied mushroom biology and, 9–10, 28
- World production, of cultivated mushrooms, 72–73, 117
- World Society for Mushroom Biology and Mushroom Products (WSMBMP), 21
- formation of, 27
- Xanthosine monophosphate (XMP), in cultivated mushrooms, 78
- Xenografts, in sclerotial antitumor and immunomodulatory studies, 133–134
- X fraction, mushroom-related hypoglycemia and, 98
- Xiang gu mushroom, 14, 35. *See also* *Lentinus edodes*
- X-ray microanalysis, of polyphosphate granules, 123
- X-ray microanalyzer, in sclerotial dietary fiber studies, 125
- Xylan
- Lentinus edodes* degradation of, 60
 - from mushrooms, 152, 156
- Xylanase genes, in *Lentinus edodes* transcriptional regulation, 56
- Xylaria nigripes*, cultivation of sclerotia of, 117
- Xylogalactoglucan, from mushrooms, 156
- Xyloglucan, from mushrooms, 152, 155, 156
- Xyloglucan–protein complex, from mushrooms, 158, 159
- Xyloglucomannan, from mushrooms, 157
- Xylomannan, from mushrooms, 156
- Xylopyranosyl residues, mushroom-related hypoglycemia and, 98
- Xylose, in cultivated mushroom dietary fiber, 78
- xyn11A* gene, in *Lentinus edodes*, 60
- Yeast, in sclerotial antitumor and immunomodulatory studies, 133
- Yeast two-hybrid system, in *Lentinus edodes* genetics, 51, 54
- Yellowness, of sclerotial dietary fiber, 126
- Yunnan Province, *Pleurotus tuber-regium* consumption in, 118
- Zero emissions, 28
- Zinc
- in cultivated mushrooms, 76
 - in vitro sclerotial binding of, 128–129
 - in *Lentinus edodes* primordium formation, 38–43
 - in sclerotial dietary fiber, 125
- Zygomycota, classification of, 80
- Zyosan, in sclerotial antitumor and immunomodulatory studies, 133